Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 43
Encontrada(s) 1 página(s)

Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

Blood eosinophil count and airway epithelial transcriptome relationships in COPD versus asthma

  • George, Leena
  • Esteve-Codina, Anna
  • Soler Artigas, María
  • Thun, Gian Andri
  • Heath, Simon
  • Gut, Ivo Glynne
  • Brightling, Christopher E.
BACKGROUND: Whether the clinical or pathophysiologic significance of the "treatable trait" high blood eosinophil count in COPD is the same as for asthma remains controversial. We sought to determine the relationship between the blood eosinophil count, clinical characteristics and gene expression from bronchial brushings in COPD and asthma. METHODS: Subjects were recruited into a COPD (emphysema versus airway disease [EvA]) or asthma cohort (Unbiased BIOmarkers in PREDiction of respiratory disease outcomes, U-BIOPRED). We determined gene expression using RNAseq in EvA (n = 283) and Affymetrix microarrays in U-BIOPRED (n = 85). We ran linear regression analysis of the bronchial brushings transcriptional signal versus blood eosinophil counts as well as differential expression using a blood eosinophil > 200 cells/μL as a cut-off. The false discovery rate was controlled at 1% (with continuous values) and 5% (with dichotomized values). RESULTS: There were no differences in age, gender, lung function, exercise capacity and quantitative computed tomography between eosinophilic versus noneosinophilic COPD cases. Total serum IgE was increased in eosinophilic asthma and COPD. In EvA, there were 12 genes with a statistically significant positive association with the linear blood eosinophil count, whereas in U-BIOPRED, 1197 genes showed significant associations (266 positive and 931 negative). The transcriptome showed little overlap between genes and pathways associated with blood eosinophil counts in asthma versus COPD. Only CST1 was common to eosinophilic asthma and COPD and was replicated in independent cohorts. CONCLUSION: Despite shared "treatable traits" between asthma and COPD, the molecular mechanisms underlying these clinical entities are predominately different., This work was funded in part by Airway Disease Predicting Outcomes through Patient Specific Computational Modelling (AirPROM) project (funded through FP7 EU grant), U‐BIOPRED (IMI) (No. 115010), eTRIKS (IMI) (No. 115446), Emphysema versus Airways Disease (EvA FP7; 200506)
Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

Towards a European health research and innovation cloud (HRIC)

  • Aarestrup, Frank M.
  • Gut, Ivo Glynne
  • Sanz, Ferran
  • Van Oyen, Herman
The European Union (EU) initiative on the Digital Transformation of Health and Care (Digicare) aims to provide the conditions necessary for building a secure, flexible, and decentralized digital health infrastructure. Creating a European Health Research and Innovation Cloud (HRIC) within this environment should enable data sharing and analysis for health research across the EU, in compliance with data protection legislation while preserving the full trust of the participants. Such a HRIC should learn from and build on existing data infrastructures, integrate best practices, and focus on the concrete needs of the community in terms of technologies, governance, management, regulation, and ethics requirements. Here, we describe the vision and expected benefits of digital data sharing in health research activities and present a roadmap that fosters the opportunities while answering the challenges of implementing a HRIC. For this, we put forward five specific recommendations and action points to ensure that a European HRIC: i) is built on established standards and guidelines, providing cloud technologies through an open and decentralized infrastructure; ii) is developed and certified to the highest standards of interoperability and data security that can be trusted by all stakeholders; iii) is supported by a robust ethical and legal framework that is compliant with the EU General Data Protection Regulation (GDPR); iv) establishes a proper environment for the training of new generations of data and medical scientists; and v) stimulates research and innovation in transnational collaborations through public and private initiatives and partnerships funded by the EU through Horizon 2020 and Horizon Europe., The workshop participants received funding from the European Union Seventh Program for Research, Technological Development and Demonstration (FP7) and Horizon Research and Innovation Program (H2020) and other European Union programs under the following grant agreements: AETIONOMY (Developing an Aetiology-based Taxonomy of Human Disease—Approaches to Develop a New Taxonomy for Neurological Disorders, IMI-no115568), ANTI-SUPERBUG PCP (ANTISUPERBUG Precommercial Procurement, H2020-no688878), B-CAST (Breast CAncer Stratification understanding the determinants of risk and prognosis of molecular sub-types, H2020-no633784), BRIDGE Health (Bridging information and data generation for evidence-based health policy and research, H2020-no664691), CASyM (Coordinating Action Systems Medicine—Implementation of Systems Medicine across Europe, FP7-n°305033), CENTER-TBI (Collaborative European NeuroTrauma Effectiveness Research in TBI, FP7-no602150), CECM (Centre for New Methods in Computational Diagnostics and Personalized Therapy, H2020-no763734), COLOSSUS (Advancing a Precision Medicine Paradigm in Metastatic Colorectal Cancer: Systems based patient stratification solutions, H2020-no754923), COMPARE (COllaborative Management Platform for detection and Analyses of (Re-)emerging and foodborne outbreaks in Europe, H2020-no643476), CONNECARE (Personalized Connected Care for Complex Chronic Patients, H2020-no689802), CREATIVE (Collaborative REsearch on ACute Traumatic brain Injury in intensiVe care medicine in Europe, FP7-no602714), DEFORM (Define the global and financial impact of research misconduct H2020-no710246), ECCTR (European Cornea and Cell Transplant Registry, FP7-n°709723), E-COMPARED (European COMPARative Effectiveness Research on online Depression, FP7-no603098), ECRIN-IA (European Clinical Research Infrastructures Network- Integrating Activity, FP7-no284395), EHR4CR (Electronic Health Records Systems for Clinical Research, IMI-no115189) eInfraCentral (European E-infrastructures Services Gateway, H2020-no731049), ELIXIR (European Life-science Infrastructure for Biological Information, FP7-n°211601), ELIXIR-EXCELERATE (Fast track ELIXIR implementation and drive early user exploitation across the life sciences, H2020-no676559), eMEN (e-mental health innovation and transnational implementation platform North West Europe, H2020), EMIF (European Medical Information Framework, IMI-no115372), ERA PerMed (ERA-net Cofund in Personalized Medicine, H2020-no779282), eTRIKS (Delivering European Translational Information and Knowledge Management Services, IMI-1-no115446), EuroPOND (Data-driven models for progression of neurological diseases, H2020-n°666992), EurValve (Personalized Decision Support for Heart Valve disease, H2020-no689617), HBP SGA1/SGA2 (Human Brain Project specific grant agreements, H2020-n°720270/785907), ICT4DEPRESSION (User-friendly ICT tools to enhance self-management and effective treatment of depression in the EU, FP7-n°248778), ImpleMentAll (Towards evidence-based tailored implementation strategies for eHealth, H2020-no733025), INSTRUCT-ULTRA (Releasing the full potential of instruct to expand and consolidate infrastructure services for integrated structural life sciences research, H2020-no731005), MASTERMIND (Management of Mental Disorders through Advanced Technologies, CIP-no621000), MeDALL (Mechanisms of the Development of ALLergy, FP7-n°261357), MedBioinformatics (Creating medically-driven integrative bioinformatics applications focused on oncology, CNS disorders and their comorbidities, H2020-n°634143), MIDAS (Meaningful Integration of Data, Analytics and Services, H2020-no727721), MultipleMS (Multiple manifestations of genetic and non-genetic factors in Multiple Sclerosis disentangled with a multi-omics approach to accelerate personalized medicine, H2020-no733161), myPEBS (Randomized Comparison Of Risk-Stratified versus Standard Breast Cancer Screening European Women Aged 40–74, H2020-no755394), OpenAIRE-Advance (Advancing Open Scholarship, H2020-no777541), OpenMedicine (OpenMedicine, H2020-n°643796), PanCareSurFup (PanCare Childhood and Adolescent Cancer Survival Care and Follow-up Studies, FP7-n°257505), PIONEER (Prostate Cancer DIagnOsis and TreatmeNt Enhancement through the Power of Big Data in EuRope, H2020-IMI-2-n°777492), PREPARE (Platform for European Preparedness Against (Re-)emerging Epidemics, FP7-n°602525), Regions4PerMed (Interregional coordination for a deep and fast uptake of personalized health, H2020-no825812), RD-CONNECT (An integrated platform connecting registries, biobanks and clinical bioinformatics for rare disease research, FP7-no305344), Solve-RD (Solving the unsolved Rare Diseases, H2020-no779257), SPIDIA4P (SPIDIA for Personalized Medicine-Standardization of generic Pre-analytical procedures for In-vitro DIAgnostics for Personalized Medicine, H2020-no733112), SYSCID (A Systems medicine approach to chronic inflammatory disease, H2020-no733100), SysCLAD (Systems prediction of Chronic Allograft Dysfunction, FP7-n°305457), SYSCOL (Systems Biology of Colorectal Cancer, FP7-no258236), SysMedPD (Systems Medicine of Mitochondrial Parkinson’s Disease, H2020-n°668738), U-BIOPRED (Unbiased BIOmarkers for the PREDiction of respiratory disease outcomes, IMI-n°115010), VPH-share (Virtual Physiological Human: Sharing for Healthcare—A Research Environment, FP7-n°269978).
Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

Systems medicine and integrated care to combat chronic noncommunicable diseases

  • Bousquet, Jean
  • Antó i Boqué, Josep Maria
  • Auffray, Charles
We propose an innovative, integrated, cost-effective health system to combat major non-communicable diseases (NCDs), including cardiovascular, chronic respiratory, metabolic, rheumatologic and neurologic disorders and cancers, which together are the predominant health problem of the 21st century. This proposed holistic strategy involves comprehensive patient-centered integrated care and multi-scale, multi-modal and multi-level systems approaches to tackle NCDs as a common group of diseases. Rather than studying each disease individually, it will take into account their intertwined gene-environment, socio-economic interactions and co-morbidities that lead to individual-specific complex phenotypes. It will implement a road map for predictive, preventive, personalized and participatory (P4) medicine based on a robust and extensive knowledge management infrastructure that contains individual patient information. It will be supported by strategic partnerships involving all stakeholders, including general practitioners associated with patient-centered care. This systems medicine strategy, which will take a holistic approach to disease, is designed to allow the results to be used globally, taking into account the needs and specificities of local economies and health systems., Part of the conceptual work presented has received support from the European commission FP7 projects AIRProm (Grant Agreement FP7 270194), BioSHaRE-EU (Grant Agreement FP7 261433), MeDALL (Grant Agreement FP7 264357), SYNERGY-COPD (Grant Agreement) and U-BIOPRED (Grant Agreement IMI 115010). JB, JMA, AC-T, FK, MLK, SP, CP and CA were supported by MeDALL; PJS, IMA and KFC were supported by U-BIOPRED; JR and AA were supported by SYNERGY-COPD; CB was supported by AIRProm; AC-T was supported by BioSHaRE-EU
RiuNet. Repositorio Institucional de la Universitat Politécnica de Valéncia
Publicación Artículo científico (JournalArticle)

Topological effects in ultrafast photoinduced processes between flurbiprofen and tryptophan in linked dyads and within human serum albumin

  • Tamarit-Mayo, Lorena
  • Jiménez, M Consuelo|||0000-0002-8057-4316
  • Vayá Pérez, Ignacio|||0000-0003-1682-9342
  • García-Gabarda, Laura
  • Miranda, Miguel A.
[EN] The interaction dynamics between flurbiprofen (FBP) and tryptophan (Trp) has been studied in covalently linked dyads and within human serum albumin (HSA) by means of fluorescence and ultrafast transient absorption spectroscopy. The dyads have proven to be excellent models to investigate photoinduced processes such as energy and/or electron transfer that may occur in proteins and other biological media. Since the relative spatial arrangement of the interacting units may affect the yield and kinetics of the photoinduced processes, two spacers consisting of amino and carboxylic groups separated by a cyclic or a long linear hydrocarbon chain (1 and 2, respectively) have been used to link the (S)- or (R)-FBP with the (S)-Trp moieties. The main feature observed in the dyads was a strong intramolecular quenching of the fluorescence, which was more important for the (S,S)- than for the (R,S)- diastereomer in dyads 1, whereas the reverse was true for dyads 2. This was consistent with the results obtained by simple molecular modelling (PM3). The observed stereodifferentiation in (S,S)-1 and (R,S)-1 arises from the deactivation of (1)Trp*, while in (S,S)-2 and (R,S)-2 it is associated with (FBP)-F-1*. The mechanistic nature of (FBP)-F-1* quenching is ascribed to energy transfer, while for (1)Trp* it is attributed to electron transfer and/or exciplex formation. These results are consistent with those obtained by ultrafast transient absorption spectroscopy, where (FBP)-F-1* was detected as a band with a maximum at ca. 425 nm and a shoulder at similar to 375 nm, whereas Trp did not give rise to any noticeable transient. Interestingly, similar photoprocesses were observed in the dyads and in the supramolecular FBP@HSA complexes. Overall, these results may aid to gain a deeper understanding of the photoinduced processes occurring in protein-bound drugs, which may shed light on the mechanistic pathways involved in photobiological damage., Grant PID2020-115010RB-I00 funded by MCIN/AEI/10.13039/501100011033 and grant from Conselleria d'Innovacio, Universitats, Ciencia i Societat Digital (CIAICO/2021/061) are gratefully acknowledged.
RiuNet. Repositorio Institucional de la Universitat Politécnica de Valéncia
Publicación Artículo científico (JournalArticle)

Solar-assisted photocatalytic water splitting using defective UiO-66 solids from modulated synthesis

  • Rueda-Navarro, Celia Maria|||0000-0002-9569-7722
  • Cabrero-Antonino, Maria
  • Atienzar Corvillo, Pedro Enrique|||0000-0002-0356-021X
  • Ferrer Ribera, Rosa Belén
  • Vayá Pérez, Ignacio|||0000-0003-1682-9342
  • Garcia-Baldovi, Hermenegildo
  • Navalón Oltra, Sergio|||0000-0001-8423-0759
  • Escamilla, Paula
  • Díez-Cabanes, Valentín
  • Fan, Dong
  • Maurin, Guillaume
[EN] Metal-organic frameworks (MOFs) are attracting increasing interests as photocatalysts for solar-driven hydrogen production from water. This paper reports on a comparative study of using either acetic acid (AA) or trifluoroacetic acid (TFA) as the representative UiO-66 organic modulators for synthesizing visible light responsive UiO-66(Zr)-X (X: NH2 or NO2) photocatalysts for water splitting. The results show that photocatalytic hydrogen generation from a water/methanol mixture can be improved by varying the nature and amount of the modulator employed to prepare the different UiO-66(Zr)-X (X: NH2 or NO2) solid derivatives. UiO-66(Zr)-NH2 was the most active photocatalyst, followed by UiO-66(Zr)-NO2, both prepared with 12 equivalents of AA with respect to the organic ligand. This UiO-66(Zr)-NH2 solid was more active than the parent MOF in photocatalytic overall water splitting (OWS) (H-2 and O-2 production of 450 and 160 mu mol.g(-1), respectively, in 5 h; apparent quantum yield (AQY) at 400 nm of 0.06%) in the absence of methanol and compares favourably with analogous reports. Information on the photocatalytic activity of the most active solids of both series was obtained by means of a series of techniques, including ultraviolet-visible (UV-vis) diffuse reflectance, X-ray photoelectron spectroscopy (XPS), laser flash photolysis (LFP), electron spin resonance (ESR), photoluminescence and photoelectrochemical measurements together with density functional theory (DFT) calculations. The results showed that organic acid modulators can be used to enhance the photocatalytic activity of missing linker UiO-66 defective materials in solar-powered water splitting., C. M. R. thanks the support of PRE2019-089877 funded by MCIN/AEI/10.13039/501100011033 and by ESF Investing in your future. V. D-C. is grateful to the European Union's Horizon 2020 Research and Innovation Program project MOF2H2 (GA No. 101084131) for the financial support. Computational ressources were provided by the Centre informatique national de l'enseignement superieur (CINES) Supercomputing facilities and the local ICGM clusters. I. V. thanks the support of grant PID2020-115010RB-I00 funded by MCIN/AEI/10.13039/501100011033. S. N. thanks the support of grant PID2021-123856OBI00 funded by MCIN/AEI/10.13039/501100011033 and by ERDF A way of making Europe.
RiuNet. Repositorio Institucional de la Universitat Politécnica de Valéncia
Publicación Artículo científico (JournalArticle)

Photolytic splitting of homodimeric quinone-derived oxetanes studied by ultrafast transient absorption spectroscopy and quantum chemistry

  • Blasco-Brusola, Alejandro
  • Tamarit-Mayo, Lorena
  • Vayá Pérez, Ignacio|||0000-0003-1682-9342
  • Navarrete-Miguel, Miriam
  • Roca-Sanjuán, Daniel
  • Miranda, Miguel A.
[EN] The photoinduced cycloreversion of oxetane derivatives is of considerable biological interest since these compounds are involved in the photochemical formation and repair of the highly mutagenic pyrimidine (6-4) pyrimidone DNA photoproducts ((6-4)PPs). Previous reports have dealt with the photoreactivity of heterodimeric oxetanes composed mainly of benzophenone (BP) and thymine (Thy) or uracil (Ura) derivatives. However, these models are far from the non-isolable Thy <degrees > Thy dimers, which are the real precursors of (6-4)PPs. Thus, we have synthesized two chemically stable homodimeric oxetanes through the Patern & ograve;-B & uuml;chi reaction between two identical enone units, i.e. 1,4-benzoquinone (BQ) and 1,4-naphthoquinone (NQ), that led to formation of BQ-Ox and NQ-Ox, respectively. Their photoreactivity has been studied by means of steady-state photolysis and transient absorption spectroscopy from the femtosecond to the microsecond time scale. Thus, photolysis of BQ-Ox and NQ-Ox led to formation of the monomeric BQ or NQ, respectively, through ring opening in a "non-adiabatic" process. Accordingly, the transient absorption spectra of the triplet excited quinones (3BQ* and 3NQ*) were not observed as a result of direct photolysis of the quinone-derived oxetanes. In the case of NQ-Ox, a minor signal corresponding to 3NQ* was detected; its formation was ascribed to minor photodegradation of the oxetane during acquisitions of the spectra during the laser experiments. These results are supported by computational analyses based on density functional theory and multiconfigurational quantum chemistry (CASSCF/CASPT2); here, an accessible conical intersection between the ground and excited singlet states has been characterized as the main structure leading to deactivation of excited BQ-Ox or NQ-Ox. This behavior contrasts with those previously observed for heterodimeric thymine-derived oxetanes, where a certain degree of ring opening into the excited triplet state is observed.; The photocleavage of homodimeric quinone oxetanes evolves through a non-adiabatic process, the opposite of what has been observed with heterodimeric oxetanes. This is explained by ultrafast transient absorption spectroscopy and quantum chemistry., Grants PID2020-115010RB-I00 and PID2021-127199NB-I00 funded by MCIN/AEI/10.13039/501100011033 and grants from Conselleria d'Innovacio, Universitats, Ciencia i Societat Digital (CIAICO/2021/061, CIAICO/2022/121 and CIAPOS/2021/87) are gratefully acknowledged. M. N.-M. is thankful to the Universitat de Valencia for her ''Atraccio de Talent 2020'' predoctoral grant. The authors would like to thank the use of RIAIDT-USC analytical facilities for the X-ray crystallography analysis
RiuNet. Repositorio Institucional de la Universitat Politécnica de Valéncia
Publicación Tesis de maestría (MasterThesis)

Estudio de los procesos fotoinducidos en la interacción del fármaco Vandetanib con luz UVA, Study of photoinduced processes in the interaction of the drug Vandetanib with UVA light, Estudi dels processos fotoinduïts en la interacció del fàrmac Vandetanib amb llum UVA

  • Falcón Fernández, Cristina
[ES] En el presente Trabajo de Fin de Máster se ha realizado un estudio exhaustivo sobre la fotorreactividad del fármaco Vandetanib (VAN), un inhibidor de la tirosina quinasa (TKI) actualmente utilizado para el tratamiento del cáncer medular de tiroides. Este trabajo combina estudios fotofísicos y fotoquímicos en medio orgánico y biológico, usando técnicas espectroscópicas como la fluorescencia y la absorción transitoria, con el objetivo de entender los procesos fotoinducidos que pueden ocurrir tras irradiar el fármaco con luz UVA. Se ha caracterizado las propiedades fotofísicas de VAN en disolventes orgánicos, detectándose distintas especies en su estado excitado dependiendo de la polaridad del medio: estados localizados singlete (LE) vs. estados de transferencia de carga intramolecular (ICT). Los estudios de fotólisis de destello láser (LFP) muestran la formación del estado excitado triplete de VAN (3VAN*), el cual se ha caracterizado por experimentos de desactivación con oxígeno molecular. Adicionalmente, se han estudiado las especies transitorias formadas en medio biológico, específicamente en presencia de albúmina sérica humana (HSA) y α1-glicoproteína ácida (HAG): principalmente se forman estados LE, mientras que 3VAN* no se genera. Por otro lado, la fuerza de interacción fármaco@proteína se ha determinado mediante medidas de fluorescencia, siendo algo mayor para HAG. La reactividad fotoquímica del fármaco se ha investigado en medio orgánico y en presencia de proteínas. Se observa mayor reactividad en disolventes orgánicos, no detectándose diferencias significativas entre medio aeróbico y anaeróbico. Esto indica que la fotorreactividad de VAN debe originarse principalmente desde estados singlete y/o de transferencia de carga, lo que queda reflejado por la mayor reactividad en hexano que en MeCN, así como por la baja reactividad en PBS. Finalmente, en vista que 3VAN* no se genera en medio proteico, y por tanto, tampoco se forma oxígeno singlete, se puede presuponer que el daño fotobiológico originado por el fármaco debe seguir un mecanismo de Tipo I., [EN] This Master's Thesis presents an exhaustive study of the photoreactivity of the drug Vandetanib (VAN), a tyrosine kinase inhibitor (TKI) currently used for the treatment of medullary thyroid cancer. This work combines photophysical and photochemical studies in organic and biological media, using spectroscopic techniques such as fluorescence and transient absorption, with the aim of understanding the photoinduced processes that may occur after irradiating the drug with UVA light. The photophysical properties of VAN have been characterized in organic solvents, detecting different species in its excited state depending on the polarity of the medium: localized singlet states (LE) vs. intramolecular charge transfer (ICT) states. Laser flash photolysis (LFP) studies show the formation of the excited triplet state of VAN (3VAN*), which has been characterized by deactivation experiments with molecular oxygen. In addition, the transient species formed in biological media, specifically in the presence of human serum albumin (HSA) and α1-acid glycoprotein (HAG), have been studied: LE states are mainly formed, while 3VAN* is not generated. On the other hand, the strength of drug@protein interactions has been determined by fluorescence measurements, being slightly higher for HAG. The photochemical reactivity of the drug has been investigated in organic media and in the presence of proteins. Greater reactivity is observed in organic solvents, with no significant differences detected between aerobic and anaerobic media. This indicates that the photoreactivity of VAN must originate mainly from singlet and/or charge transfer states, which is reflected by the higher reactivity in hexane than in MeCN, as well as by the low reactivity in PBS. Finally, given that 3VAN* is not generated in protein media, and therefore, singlet oxygen is not formed either, it can be assumed that the photobiological damage caused by the drug must follow a Type I mechanism., [CA] En el present Treball de Fi de Màster s'ha realitzat un estudi exhaustiu sobre la fotorreactivitat del fàrmac vandetanib (VAN), un inhibidor de la tirosina cinasa (TKI) actualment utilitzat per al tractament del càncer medul·lar de tiroide. Este treball combina estudis fotofísics i fotoquímics al mig orgànic i biològic, usant tècniques espectroscòpiques com la fluorescència i l'absorció transitòria, amb l'objectiu d'entendre els processos fotoinduïts que poden ocórrer després d'irradiar el fàrmac amb llum UVA. S'ha caracteritzat les propietats fotofísiques de VAN en dissolvents orgànics, detectant-se diferents espècies en el seu estat excitat depenent de la polaritat del mitjà: estats localitzats singulet (LE) vs. estats de transferència de càrrega intramolecular (ICT). Els estudis de fotòlisis de centelleig làser (LFP) mostren la formació de l'estat excitat triplet de VAN (3VAN*), el qual s'ha caracteritzat per experiments de desactivació amb oxigen molecular. Addicionalment, s'ha estudiat les espècies transitòries formades al mig biològic, específicament en presència d'albúmina sèrica humana (HSA) i α1-glicoproteïna àcida (HAG): principalment es formen estats LE, mentres que 3VAN* no es genera. D'altra banda, la força d'interacció fàrmac@proteina s'ha determinat mitjançant mesures de fluorescència, sent una mica major per a HAG. La reactivitat fotoquímica del fàrmac s'ha investigat al mig orgànic i en presència de proteïnes. S'observa major reactivitat en dissolvents orgànics, no detectant-se diferències significatives entre mig aeròbic i anaeròbic. Això indica que la fotorreactivitat de VAN ha d'originar-se principalment des d'estats singulet i/o de transferència de càrrega, la qual cosa queda reflectit per la major reactivitat en hexà que en MeCN, així com per la baixa reactivitat en PBS. Finalment, en vista que 3VAN* no es genera al mig proteic, i per tant, tampoc es forma oxigen singulet, es pot pressuposar que el mal fotobiològic originat pel fàrmac ha de seguir un mecanisme de Tipus I.
RiuNet. Repositorio Institucional de la Universitat Politécnica de Valéncia
Publicación Artículo científico (JournalArticle)

Photoprocesses of the tyrosine kinase inhibitor gefitinib: from femtoseconds to microseconds and from solution to the cell

  • Tamarit-Mayo, Lorena
  • Andreu, Inmaculada|||0000-0003-3409-9443
  • Vayá Pérez, Ignacio|||0000-0003-1682-9342
  • El Ouardi, Meryem
  • Miranda Alonso, Miguel Ángel
[EN] Gefitinib (GFT) is a tyrosine kinase inhibitor currently used for the treatment of metastatic non-small cell lung cancer. Although it has been suggested that GFT can be phototoxic, there are no systematic studies on this issue. Here, the photosensitizing potential of GFT has been assessed by means of NRU assays and protein photooxidation. In addition, a thorough photophysical study is presented based on ultrafast transient absorption spectroscopy, fluorescence and laser flash photolysis. Transient species generated after excitation of GFT have been characterized in solution and in biological environments (i.e. HSA and HaCaT cells) to gain insight into the mechanisms involved in photodamage. The photobehavior of GFT was strongly medium-dependent. Excitation of the drug resulted in the formation of locally excited (LE) singlet states ((1)GFT*), which were found to be the main emissive species in non-polar solvents and also within HSA and HaCaT cells. By contrast, in polar solvents, LE states rapidly evolved (similar to 1 ps) towards the formation of longer-lived intramolecular charge transfer (ICT) states. The triplet excited state of GFT ((3)GFT*) can be formed through intersystem crossing from (1)GFT* in non-polar solvents and from ICT states in the polar ones, or in the particular case of ethanol, by photosensitization using 2-methoxyacetophenone as an energy donor. In the HSA environment, (3)GFT* was hardly detected due to quenching of its LE (1)GFT* precursor by Trp through an electron transfer process. Accordingly, HSA photooxidation by GFT was demonstrated using the protein carbonylation method. In summary, a good correlation is established between the photophysical behavior and the photobiological properties of GFT, which provides a mechanistic basis for the observed phototoxicity., Financial support from the Spanish Government (RYC-2015-17737, CTQ2017-89416-R, BEAGAL 18/00211, FPU19/00048 and PID2020-115010RB-I00; the Carlos III Institute (ISCIII) of Health, grants: PI16/01877, and CPII16/00052) and Conselleria d'Educacio, Cultura i Esport (PROMETEO/2017/075) is gratefully acknowledged.
RiuNet. Repositorio Institucional de la Universitat Politécnica de Valéncia
Publicación Tesis de maestría (MasterThesis)

Analysis of Photoinduced Degradation of Afatinib: Associated Photochemical and Photobiological Reactions, Análisis de la Degradación Fotoinducida del Afatinib: Reacciones Fotoquímicas y Fotobiológicas Asociadas, Anàlisi de la degradació fotoinduïda d&apos, afatinib: reaccions fotoquímiques i fotobiològiques associades

  • Leon Acero, Silvia Valentina
[ES] El cáncer de pulmón es la principal causa de muerte por cáncer a nivel mundial, siendo el carcinoma pulmonar de células no pequeñas (NSCLC) el subtipo más común. La mayoría de los pacientes se diagnostican en etapas avanzadas, donde las terapias locorregionales ya no son efectivas. En este contexto, el hallazgo de mutaciones en el receptor EGFR ha impulsado el desarrollo de terapias dirigidas, como los inhibidores de tirosina quinasa (TKIs). Entre ellos, Afatinib (AFT) destaca como un inhibidor irreversible aprobado como tratamiento de primera línea para el NSCLC.Este trabajo de fin de Máster se centra en el estudio fotoquímico y la caracterización fotofísica de Afatinib tras irradiación de luz UVA, con el objetivo de evaluar su fotoestabilidad su degradación y correlacionar los estudios fotofísicos con resultados previos de fototoxicidad.Así, se registraron los espectros de absorción y emisión en disolventes de diferente polaridad, identificando la presencia de estados excitados localizados (LE) y estados de transferencia intramolecular de carga (ICT). Además, se calcularon las energías de excitación en tolueno, acetonitrilo, ciclohexano y etanol. Se midieron los tiempos de vida de fluorescencia para entender el comportamientodependiente del disolvente. Disoluciones de AFT en tolueno y acetonitrilo se irradiaron a diferentes tiempos. Los productos de degradación fueron analizados mediante HPLC y espectroscopía de RMN de ¹H, detectando nuevas señales, sobre la región aromática, que indican transformaciones estructurales incluso tras exposiciones cortas. También se estudió su interacción con albúmina sérica humana (HSA), una importante proteína transportadora en el torrente sanguíneo. Los experimentos de fotólisis de destello láser (LFP) no mostraron señales de estados tripletes (³AFT*), descartando la formación de oxígeno singlete (¹O&#8322;) y sugiriendo mecanismos fototóxicos de tipo I. Estos resultados aportan al conocimiento del comportamiento fotoquímico de Afatinib, con implicaciones relevantes para su estabilidad, formulación y seguridad clínica., [EN] Lung cancer remains the leading cause of cancer-related deaths worldwide, with non-small cell lung carcinoma (NSCLC) accounting for most cases. A large proportion of patients are diagnosed at advanced stages, where conventional locoregional therapies are no longer viable. In this context, the discovery of mutations in the epidermal growth factor receptor (EGFR) has enabled the development of targeted therapies, including oral EGFR tyrosine kinase inhibitors (TKIs). Among these, Afatinib stands out as an irreversible, highlyselective EGFR inhibitor approved for first-line treatment of NSCLC. This study focuses on the photochemical and photophysical characterization of Afatinib under UVA irradiation to evaluateits photostability. Steady-state absorption and emission spectra were recorded in solvents of varying polarity to distinguish between locally excited (LE) and intramolecular charge transfer (ICT) states. Excited-state energies were estimated, and fluorescence lifetimes were measured to understand solvent-dependent behavior. Afatinib solutions in toluene and acetonitrile were irradiated at different times. The resulting photoproducts were analyzed by HPLC and ¹H-NMR spectroscopy. The NMR spectra showed new peaks in the aromatic region and changes in aliphatic signals, indicating structural transformations even at short exposure times. These results confirm Afatinib s photoactive character. Binding studies with human serum albumin (HSA) were also conducted to explore possible interactions in biological environments. Although laser flash photolysis (LFP) experiments did not reveal triplet excited-state signals or singlet oxygen (¹O&#8322;) formation, this supports the hypothesis that Afatinib undergoes primarily Type I phototoxic mechanisms, driven by electron or hydrogen transfer from the singlet excited state. These findings contribute to a better understanding of the photochemical behavior of AFT, with potential implications for its stability, formulation, and clinical safety profile.
RiuNet. Repositorio Institucional de la Universitat Politécnica de Valéncia
Publicación Artículo científico (JournalArticle)

Solar-driven gas phase photocatalytic CO2 methanation by multimetallic UiO-66 solids decorated with RuOx nanoparticles

  • Cabrero-Antonino, Maria
  • Melillo, Arianna
  • Alvaro Rodríguez, Maria Mercedes|||0000-0001-5070-4207
  • Ferrer Ribera, Rosa Belén
  • Vayá Pérez, Ignacio|||0000-0003-1682-9342
  • Garcia-Baldovi, Hermenegildo
  • Navalón Oltra, Sergio|||0000-0001-8423-0759
  • Montero-Lanzuela, Eva
[EN] As there is an urgent need to produce solar fuels from CO2, we here report on the development of a series of multimetallic UiO-66(Zr/Ce/Ti) solids-supported RuOx nanoparticles as photocatalysts for selective gas phase CO2 methanation by H-2 under simulated sunlight irradiation. The trimetallic UiO-66(Zr/Ce/Ti) based-photocatalyst exhibits higher activity (1,900 mu mol g(-1) of CH4 after 22 h) than analogous mono- [UiO-66(Zr) or UiO-66 (Ce)] and bimetallic [UiO-66(Zr/Ce) or UiO-66(Zr/Ti)] derivatives, as well as higher than previous reports on metal-organic frameworks (MOFs). The experimental evidence on the observed order of photocatalytic activity and insights into the occurrence of a dual photochemical and photothermal mechanism for the most active trimetallic sample were obtained by means of spectroscopic techniques including fluorescence and laser flash photolysis, photoelectrochemical and additional photocatalytic measurements. This study exemplifies the benefits of developing multimetallic MOF-supported metal nanoparticles to achieve high photocatalytic activity for solar-driven gas phase CO2 conversion., Grant FPU20/03140 funded by MCIN/mAEI/10.13039/501100011033 ESF Investing in your future. I.V. thanks the support of grant PID2020-115010RB-I00 funded by MCIN/AEI/10.13039/501100011033. S.N. thanks the support of grant PID2021-123856OB-I00 funded by MCIN/AEI/10.13039/501100011033 and by ERDF A way of making Europe. S.N acknowledges the funding for open access charge from "CRUE-Universitat Politecnica de Valencia."
RiuNet. Repositorio Institucional de la Universitat Politécnica de Valéncia
Publicación Artículo científico (JournalArticle)

Photo-thermal Catalytic CO2 Methanation by RuO x @MIL-101(Cr) with 9.2% Apparent Quantum Yield under Visible Light Irradiation

  • Ramirez-Hernandez, Juan Jose
  • Fernandes-de Almeida, Vitor
  • Ferrer Ribera, Rosa Belén
  • Llabrés i Xamena, Francesc Xavier|||0000-0002-4238-5784
  • Vayá Pérez, Ignacio|||0000-0003-1682-9342
  • Garcia-Baldovi, Hermenegildo
  • Amarajothi, Dhakshina Moorthy|||0000-0003-0991-6608
  • Navalón Oltra, Sergio|||0000-0001-8423-0759
  • Abou-Khalil, Zahraa
  • Daturi, M
  • Clet, Guillaume
  • El-Roz, Mohamad
[EN] Solar-assisted gaseous CO2 hydrogenation to CH4 is a potential strategy for favoring the transition to net zero emissions. Here, we report the development of a series of efficient metal-organic frameworks with MIL-101(Cr or Fe) topology decorated with RuOx nanoparticles (ca. 0.2-2 wt %) as heterogeneous photocatalysts for the selective methanation of CO2 by H-2 under simulated sunlight irradiation. The activity of RuOx(1 wt %)@MIL-101(Cr) is between 3 and 50 times higher than related MOF-based photocatalysts under similar reaction conditions. Among the different photocatalysts, the optimized RuOx(2 wt %)@MIL-101(Cr) photocatalyst showed 98.1% CO2 conversion with 98.8% CH4 selectivity reaching a production rate of 7.85 mmol g(-1) h(-1) with 720 mW cm(-2) at 200 degrees C. Further, this photocatalyst exhibited a record apparent quantum yield of 9.2% at 600 nm and 200 degrees C after subtracting thermal activity contribution compared to any previous MOF- or other heterogeneous-based photocatalyst reported so far. The photocatalyst retained its activity and integrity upon reuse for about 110 h. Transient photocurrent, electrochemical impedance, photoluminescence, and laser flash photolysis spectroscopies together with additional photocatalytic experiments suggest the occurrance of dual photochemical and photothermal reaction pathways. The photocatalytic CO2 methanation reaction mechanism was further investigated using operando Fourier transform infrared spectroscopy., J.J.R.-H. thanks the Universitat Politecnica de Valencia for the Ph.D. financial support of the PAID-01-21 project. I.V. appreciates the support of Grant PID2020-115010RB-I00 funded by MICIU/AEI/10.13039/501100011033. H.G.B. appreciates the support of Grant No. RYC2022-037287-I funded by MCIN/AEI/1013039/501100011033. The METHASOL project receives funding from the European Union Horizon 2020 research and innovation programme under Grant Agreement No. 10102264. Funding for open access charge: CRUE-Universitat Politecnica de Valencia. A.D. is beneficiary of a grant Maria Zambrano in Universitat Politecnica de Valencia within the framework of the grants for the retraining in the Spanish university system (Spanish Ministry of Universities, financed by the European Union, NextGeneration EU). F.X.L.X the Spanish Ministry of Science and Innovation (PID2020-112590GB-C21, PID2023-146114NB-C21, and CEX2021-001230-S grants funded by MCIN/AEI/10.13039/501100011033) for support. This study forms part of the Advanced Materials Program and was supported by MICIN with funding from European Union NextGeneration (PRTR-C17.I1) and by the Generalitat Valenciana (MFA/2022/003). M.E.-R. acknowledges the Normandy Region and the European Union for financial support (project SuntoChem). S.N. appreciates the support received from Grant PID2021-123856OB-I00 funded by MICIU/AEI/10.13039/501100011033 and by ERDF A way of making Europe.
RiuNet. Repositorio Institucional de la Universitat Politécnica de Valéncia
Publicación Artículo científico (JournalArticle)

Cellular photo(geno)toxicity of gefitinib after biotransformation

  • El Ouardi, Meryem
  • Miranda, Miguel A.
  • Tamarit-Mayo, Lorena
  • Vayá Pérez, Ignacio|||0000-0003-1682-9342
  • Andreu, Inmaculada|||0000-0003-3409-9443
[EN] Gefitinib (GFT) is a selective epidermal growth factor receptor (EGFR) inhibitor clinically used for the treatment of patients with non-small cell lung cancer. Bioactivation by mainly Phase I hepatic metabolism leads to chemically reactive metabolites such as O-Demethyl gefitinib (DMT-GFT), 4-Defluoro-4-hydroxy gefitinib (DF-GFT), and O-Demorpholinopropyl gefitinib (DMOR-GFT), which display an enhanced UV-light absorption. In this context, the aim of the present study is to investigate the capability of gefitinib metabolites to induce photosensitivity disorders and to elucidate the involved mechanisms. According to the neutral red uptake (NRU) phototoxicity test, only DF-GFT metabolite can be considered non-phototoxic to cells with a photoirritation factor (PIF) close to 1. Moreover, DMOR-GFT is markedly more phototoxic than the parent drug (PIF = 48), whereas DMT-GFT is much less phototoxic (PIF = 7). Using the thiobarbituric acid reactive substances (TBARS) method as an indicator of lipid photoperoxidation, only DMOR-GFT has demonstrated the ability to photosensitize this process, resulting in a significant amount of TBARS (similar to ketoprofen, which was used as the positive control). Protein photooxidation monitored by 2,4-dinitrophenylhydrazine (DNPH) derivatization method is mainly mediated by GFT and, to a lesser extent, by DMOR-GFT; in contrast, protein oxidation associated with DMT-GFT is nearly negligible. Interestingly, the damage to cellular DNA as revealed by the comet assay, indicates that DMT-GFT has the highest photogenotoxic potential; moreover, the DNA damage induced by this metabolite is hardly repaired by the cells after a time recovery of 18 h. This could ultimately result in mutagenic and carcinogenic effects. These results could aid oncologists when prescribing TKIs to cancer patients and, thus, establish the conditions of use and recommend photoprotection guidelines., This research was funded by the MICINN (Grant PID2020-115010RB-I00 funded by MCIN/AEI/10.13039/501100011033, RYC-2015-17737 and FPU predoctoral fellowship for ME.).
RiuNet. Repositorio Institucional de la Universitat Politécnica de Valéncia
Publicación Artículo científico (JournalArticle)

Assessment of the PARP inhibitor talazoparib photosafety profile

  • Mateos-Pujante, Alejandro
  • Jiménez, M Consuelo|||0000-0002-8057-4316
  • Andreu, Inmaculada|||0000-0003-3409-9443
[EN] Talazoparib (TLZ) is a poly(adenosine diphosphate [ADP]-ribose) polymerase inhibitor employed for the treatment of breast cancer. This drug displays an absorption band in the UVA region, and therefore investigation of the possible phototoxic side-effects associated to its administration results of enormous relevance. In this context, we describe here a photochemical and photobiological study to ascertain the photosafety profile of TLZ. Concerning transient species, the singlet and triplet excited states of TLZ were detected by fluorescence (lambda max em = 440 nm) and laser flash photolysis experiments (lambda max abs = 400 nm), respectively. Remarkably, TLZ irradiation with UVA light in aqueous solution resulted in formation of a stable photooxidated product, TLZ-P, whose absorption band is extended until the visible region. From in vitro experiments, phototoxicity was revealed for the parent drug by neutral red uptake (NRU) assays, with a PIF value of ca 7; besides, TLZ induced formation of reactive oxygen species (ROS) and produced significant damage to both proteins and DNA. By contrast, the singlet and triplet excited states of TLZ-P were not detected, and no photodamage was observed in the NRU experiments. Overall, the results indicate that TLZ induces phototoxicity, whereas its photoproduct exhibits photosafety., Grants: PID2020-115010RB-I00 and PID2022-1381890NB-I00 funded by MICIN/AEI/10.13039/501100011033 and by "ERDF A way of making Europe", CIAICO/2021/061 and ACIF/2018/153 fellowship for A. M.-P funded by Generalitat Valenciana.
RiuNet. Repositorio Institucional de la Universitat Politécnica de Valéncia
Publicación Artículo científico (JournalArticle)

Modulation of the photobehavior of gefitinib and its phenolic metabolites by human transport proteins

  • Tamarit-Mayo, Lorena
  • Andreu, Inmaculada|||0000-0003-3409-9443
  • Vayá Pérez, Ignacio|||0000-0003-1682-9342
  • El Ouardi, Meryem
  • Lence, Emilio
  • González-Bello, Concepción
  • Miranda Alonso, Miguel Ángel
[EN] The photobiological damage that certain drugs or their metabolites can photosensitize in proteins is generally associated with the nature of the excited species that are generated upon interaction with UVA light. In this regard, the photoinduced damage of the anticancer drug gefitinib (GFT) and its two main photoactive metabolites GFT-M1 and GFT-M2 in cellular milieu was recently investigated. With this background, the photophysical properties of both the drug and its metabolites have now been studied in the presence of the two main transport proteins of human plasma, i.e., serum albumin (HSA) and ¿1-acid glycoprotein (HAG) upon UVA light excitation. In general, the observed photobehavior was strongly affected by the confined environment provided by the protein. Thus, GFT-M1 (which exhibits the highest phototoxicity) showed the highest fluorescence yield arising from long-lived HSA-bound phenolate-like excited species. Conversely, locally excited (LE) states were formed within HAG, resulting in lower fluorescence yields. The reserve was true for GFT-M2, which despite being also a phenol, led mainly to formation of LE states within HSA, and phenolate-like species (with a minor contribution of LE) inside HAG. Finally, the parent drug GFT, which is known to form LE states within HSA, exhibited a parallel behavior in the two proteins. In addition, determination of the association constants by both absorption and emission spectroscopy revealed that the two metabolites bind stronger to HSA than the parent drug, whereas smaller differences were observed for HAG. This was further confirmed by studying the competing interactions between GFT or its metabolites with the two proteins using fluorescence measurements. These above experimental findings were satisfactorily correlated with the results obtained by means of molecular dynamics (MD) simulations, which revealed the high affinity binding sites, the strength of interactions and the involved amino acid residues. In general, the differences observed in the photobehavior of the drug and its two photoactive metabolites in protein media are consistent with their relative photosensitizing potentials., The Ministry of Science, Innovation and Universities of Spain, the Conselleria d'Innovacio, Universitats, Ciencia i Societat Digital, the University of Valencia, the Health Research Institute Hospital La Fe (IIS La Fe) and La Xunta de Galicia are gratefully acknowledged for financial support. All authors are grateful to the Centro de Supercomputacion de Galicia (CESGA) for use of the Finis Terrae computer.The author(s) declare that financial support was received for the research, authorship, and/or publication of this article. Grants PID2020-115010RB-I00 and PID2022-136963OB-I00 funded by MCIN/AEI/10.13039/501100011033, grant CIAICO/2021/061 funded by Conselleria d'Innovacio, Universitats, Ciencia i Societat Digital and grant AP2022-5 funded by Programa d'Accions Preparatories UV-La Fe. Grants from the Xunta de Galicia [ED431C 2021/29 and the Centro singular de investigacion de Galicia accreditation 2019-2022 (ED431G 2019/03), CG-B], and the European Regional Development Fund (ERDF).
RiuNet. Repositorio Institucional de la Universitat Politécnica de Valéncia
Publicación Artículo científico (JournalArticle)

Singlet oxygen and radical-mediated mechanisms in the oxidative cellular damage photosensitized by the protease inhibitor simeprevir

  • García-Laínez, Guillermo
  • El Ouardi, Meryem
  • Moreno, Alejandro
  • Lence, Emilio
  • González-Bello, Concepción
  • Miranda, Miguel Á.
  • Andreu, Inmaculada|||0000-0003-3409-9443
[EN] Hepatitis C, a liver inflammation caused by the hepatitis C virus (HCV), is treated with antiviral drugs. In this context, simeprevir (SIM) is an NS3/4A protease inhibitor used in HCV genotypes 1 and 4. It is orally admin-istered and achieves high virological cure rates. Among adverse reactions associated with SIM treatment, photosensitivity reactions have been reported. In the present work, it is clearly shown that SIM is markedly phototoxic, according to the in vitro NRU assay using BALB/c 3T3 mouse fibroblast. This result sheds light on the nature of the photosensitivity reactions induced by SIM in HCV patients, suggesting that porphyrin elevation in patients treated with SIM may not be the only mechanism responsible for SIM-associated photosensitivity. Moreover, lipid photoperoxidation and protein photooxidation assays, using human skin fibroblasts (FSK) and human serum albumin (HSA), respectively, reveal the capability of this drug to promote photodamage to cellular membranes. Also, DNA photo lesions induced by SIM are noticed through comet assay in FSK cells. Photo-chemical and photobiological studies on the mechanism of SIM-mediated photodamage to biomolecules indicate that the key transient species generated upon SIM irradiation is the triplet excited state. This species is efficiently quenched by oxygen giving rise to singlet oxygen, which is responsible for the oxidation of lipids and DNA (Type II mechanism). In the presence of HSA, the photobehavior is dominated by binding to site 3 of the protein, to give a stable SIM@HSA complex. Inside the complex, quenching of the triplet excited state is less efficient, which results in a longer triplet lifetime and in a decreased singlet oxygen formation. Hence, SIM-mediated photoox-idation of the protein is better explained through a radical (Type I) mechanism., Financial support from the Spanish Ministry of Science and Innovation [PID2020-115010RB-I00/AEI/10.13039/501100011033 (I.A), PID2019-105512RB-I00/AEI/10.13039/501100011033 (CG-B) and FPU predoctoral fellowship for M. El O.], Axencia Galega de Innovacion (2020-PG067, CG-B), the Xunta de Galicia [ED431C 2021/29 and the Centro singular de investigacion de Galicia accreditation 2019-2022 (ED431G 2019/03),], and the European Regional Development Fund (ERDF) is gratefully acknowledged. All authors are grateful to the Centro de Supercomputacion de Galicia (CESGA) for use of the Finis Terrae computer.
RiuNet. Repositorio Institucional de la Universitat Politécnica de Valéncia
Publicación Artículo científico (JournalArticle)

High-Energy Long-Lived Emitting Mixed Excitons in Homopolymeric Adenine-Thymine DNA Duplexes

  • Vayá Pérez, Ignacio|||0000-0003-1682-9342
  • Gustavsson, Thomas
  • Markovitsi, Dimitra
[EN] The publication deals with polymeric pA·pT and oligomeric A(20)·T(20) DNA duplexes whose fluorescence is studied by time-correlated single photon counting. It is shown that their emission on the nanosecond timescale is largely dominated by high-energy components peaking at a wavelength shorter than 305 nm. Because of their anisotropy (0.02) and their sensitivity to base stacking, modulated by the duplex size and the ionic strength of the solution, these components are attributed to mixed pi pi*/charge transfer excitons. As high-energy long-lived excited states may be responsible for photochemical reactions, their identification via theoretical studies is an important challenge., This work was supported by the European Program H2020 MSCA ITN (grant No. 765266-LightDyNAmics project) and the Spanish Agencia Estatal de Investigacion (grant number RYC-201517737 and project number PID2020-115010RB-I00).
RiuNet. Repositorio Institucional de la Universitat Politécnica de Valéncia
Publicación Artículo científico (JournalArticle)

Cytotoxic sub-nanometer aqueous platinum clusters as potential antitumoral agents

  • Greco, Rossella
  • García-Laínez, Guillermo
  • Marini, Carlo
  • Domínguez, Irene
  • Lopez-Haro, Miguel
  • Hernandez-Garrido, Juan Carlos
  • Cerón-Carrasco, José Pedro
  • Oliver-Meseguer, Judit|||0000-0003-1555-3583
  • Andreu, Inmaculada|||0000-0003-3409-9443
  • Leyva Perez, Antonio|||0000-0003-1063-5811
[EN] Ligand-free sub-nanometer metal clusters (MCs) of Pt, Ir, Rh, Au and Cu, are prepared here in neat water and used as extremely active (nM) antitumoral agents for HeLa and A2870 cells. The preparation just consists of adding the biocompatible polymer ethylene-vinyl alcohol (EVOH) to an aqueous solution of the corresponding metal salt, to give liters of a MC solution after filtration of the polymer. Since the MC solution is composed of just neat metal atoms and water, the intrinsic antitumoral activity of the different sub-nanometer metal clusters can now fairly be evaluated. Pt clusters show an IC50 of 0.48 mu M for HeLa and A2870 cancer cells, 23 times higher than that of cisplatin and 1000 times higher than that of Pt NPs, and this extremely high cytotoxicity also occurs for cisplatin-resistant (A2870 cis) cells, with a resistance factor of 1.4 (IC50 = 0.68 mu M). Rh and Ir clusters showed an IC50 similar to 1 mu M. Combined experimental and computational studies support an enhanced internalization and cytotoxic activation., This work was supported by MINECO (Spain, Projects CTQ 2017-86735-P [AEI/FEDER, UE], PID2020-115010RB-I00, BEAGAL 18/00211, MAT2017-87579-R, IJC2018-036514-I and SEV-2016-0683). Financial support by the project PID2020-115100GB-I00 (funded by Spanish MCIINN, MCIN/AEI/10.13039/501100011033MICIIN) is acknowledged. STEM studies were performed at the DME-UCA node of the National Unique Infrastructure for Electron Microscopy of Materials, ELECMI. Theoretical calculations were conducted in the Poznan Supercomputing Center and in the Plataforma Andaluza de Bioinformatica located at the Universidad Malaga, Spain. The proteomic analysis was performed in the proteomics facility of the SCSIE University of Valencia. We gratefully acknowledge ALBA synchrotron for allocating beamtime and CL AE SS beamline staff for their technical support during our experiment. R. G. thanks ITQ for the concession of a contract. We also thank M. T. Minguez-Hernandez (SCSIE, UV) for the preparation of ultramicrotome samples.
RiuNet. Repositorio Institucional de la Universitat Politécnica de Valéncia
Publicación Artículo científico (JournalArticle)

Solar Gas-Phase CO2 Hydrogenation by Multifunctional UiO-66 Photocatalysts

  • Rueda-Navarro, Celia Maria|||0000-0002-9569-7722
  • Melillo, Arianna
  • Vayá Pérez, Ignacio|||0000-0003-1682-9342
  • Navalón Oltra, Sergio|||0000-0001-8423-0759
  • Abou Khalil, Zahraa
  • Ferrer, Belen
  • Montero, Raul
  • Longarte, Asier
  • Daturi, Marco
  • El-Roz, Mohamad
  • Martínez-Martínez, Virginia
  • Baldovi, Herme G.
[EN] Solar-assisted CO2 conversion into fuels and chemical products involves a range of technologies aimed at driving industrial decarbonization methods. In this work, we report on the development of a series of multifunctional metal-organic frameworks (MOFs) based on nitro- or amino-functionalized UiO-66(M) (M: Zr or Zr/Ti) supported RuOx NPs as photocatalysts, having different energy band level diagrams, for CO2 hydrogenation under simulated concentrated sunlight irradiation. RuOx(1 wt %; 2.2 +/- 0.9 nm)@UiO-66(Zr/Ti)-NO2 was found to be a reusable photocatalyst, to be selective for CO2 methanation (5.03 mmol g(-1) after 22 h;, apparent quantum yield at 350, 400, and 600 nm of 1.67, 0.25, and 0.01%, respectively), and to show about 3-6 times activity compared with previous investigations. The photocatalysts were characterized by advanced spectroscopic techniques like femto- and nanosecond transient absorption, spin electron resonance, and photoluminescence spectroscopies together with (photo)electrochemical measurements. The photocatalytic CO2 methanation mechanism was assessed by operando FTIR spectroscopy. The results indicate that the most active photocatalyst operates under a dual photochemical and photothermal mechanism. This investigation shows the potential of multifunctional MOFs as photocatalysts for solar-driven CO2 recycling., C.M.R.N. thanks the support of PRE2019-089877 funded by MICIU/AEI/10.13039/501100011033. I.V. thanks the support of grant PID2020-115010RB-I00 funded by MICIU/AEI/10.13039/501100011033. A.L. thanks the support from the MICIU through grant PID2021-127918NB-I00. V.M.M. thanks financial support of grants PID2020-114347RB-C32 funded by MICIU/AEI/10.13039/501100011033 as well as Vasco-Eusko Jaurlaritza (project IT1639-22) and by ERDF "A way of making Europe". The METHASOL project receives funding from the European Union Horizon 2020 research and innovation programme under Grant Agreement N degrees 10102264. Funding for open access charge: CRUE-Universitat Politecnica de Valencia. S.N. thanks the support of grant PID2021-123856OBI00 funded by MICIU/AEI/10.13039/501100011033 and by ERDF "A way of making Europe".
RiuNet. Repositorio Institucional de la Universitat Politécnica de Valéncia
Publicación Artículo científico (JournalArticle)

Evaluation of phototoxicity induced by the anticancer drug rucaparib

  • Mateos-Pujante, Alejandro
  • Jiménez, M Consuelo|||0000-0002-8057-4316
  • Andreu, Inmaculada|||0000-0003-3409-9443
[EN] Rucaparib (RCP) is a potent selective inhibitor of both PARP-1 and PARP-2 enzymes that induces synthetic lethality in cancer cells. It is used for the treatment of breast and ovarian tumors harboring deleterious germline or somatic cancer susceptibility genes mutations. Although RCP has an indole chromophore in its structure, it displays a bathochromic shift of the absorption band towards the UVA region of sunlight, thus extending the active fraction of solar light able to produce photosensitivity reactions. In this context, it is highly interesting to study the photo(geno)toxicity disorders associated with this drug, bearing in mind that, for dermatologists it is crucial to understand the toxicity mechanism to improve clinical management. In the present work, RCP has shown to be potentially phototoxic, as observed in the neutral red uptake phototoxicity test. Moreover, this significant phototoxicity is attributed to both proteins and genomic DNA, as revealed in the protein photooxidation and comet assays. The results obtained are highly relevant concerning RCP photosafety and become clinically important in the context of identification of the cutaneous adverse events that can be associated with the targeted therapies. Interestingly, this is the first example of a PARP inhibitor able to induce photosensitized damage to biomolecules., The present work was supported by: the Spanish Government (PID2019-105391GB-C22, PID2020-115010RB-100 and BEAGAL 18/00211) and Generalitat Valenciana (ACIF/2018/153 fellowship for A. M-P). We would also like to thank IIS La Fe Microscopy Unit for technical assistance.
RiuNet. Repositorio Institucional de la Universitat Politécnica de Valéncia
Publicación Tesis doctoral (DoctoralThesis)

Evaluación del potencial fotoquímico y fotobiológico de los inhibidores de la poli (ADP-ribosa) polimerasa

  • Mateos Pujante, Alejandro
[ES] En la presente tesis doctoral se ha desarrollado una metodología multidisciplinar para la evaluación del potencial fotoquímico y fotobiológico in vitro de los fármacos inhibidores de la poli (ADP-ribosa) polimerasa (PARP), combinando tanto estudios fotofísicos y de caracterización como estudios fotobiológicos en biomoléculas modelo y en cultivos celulares, concretamente en queratinocitos humanos inmortalizados (HaCaT). Así, el objetivo general es investigar si estos fármacos, en combinación con la radiación solar, son capaces de inducir reacciones de fotosensibilidad y, por tanto, poder alertar a los oncólogos de estos hallazgos para que puedan indicar pautas de fotoprotección adecuadas a sus pacientes, y así prevenir estos efectos indeseados. Esta tesis se divide en un total de 7 capítulos. En el primero (introducción), se recogen los hitos más importantes relacionados con los inhibidores de la PARP, así como un resumen acerca de las reacciones de fotosensibilización y de los mecanismos químicos y biológicos involucrados en las mismas. Tras una exhaustiva búsqueda bibliográfica acerca de estos fármacos, se hizo un primer cribado de los cinco de la tercera y última generación (rucaparib, talazoparib, niraparib, olaparib y veliparib), identificando así tres de ellos como posibles agentes fotosensibilizantes: rucaparib, talazoparib y niraparib, cuyo estudio se describe en profundidad en los capítulos 4, 5 y 6 de la tesis. En el capítulo 4 se evalúa la fototoxicidad del rucaparib (RCP), un fármaco que, a pesar de tener un cromóforo indol en su estructura química, posee un desplazamiento batocrómico hacia la región UVA de la luz solar, siendo así capaz de inducir reacciones de fotosensibilidad. Se observó mediante experimentos de fluorescencia y fotólisis de destello láser que, tras absorción de luz en esta región del espectro, tiene lugar la generación de especies reactivas de oxígeno (ROS), que podrían ser las responsables de generar un daño fotooxidativo hacia el ADN celular y a las proteínas transmembranales, originando como resultado una foto(geno)toxicidad. Además, se estableció que el mecanismo de la muerte celular fotoinducida por RCP es por apoptosis. El capítulo 5 se centra en la evaluación del perfil de fotoseguridad de talazoparib (TLZ), el cual, tras su irradiación con luz UVA da lugar a un fotoproducto que, tras su aislamiento y caracterización, resultó no presentar fotorreactividad. Este fotoproducto resultó además ser el responsable de reducir significativamente el potencial fototóxico del fármaco original, ya que no se detectaron especies transitorias tras su irradiación con luz UVA. Además, para el TLZ se reveló la producción in vitro de ROS, especies que podrían ser las responsables de generar un daño fotooxidativo tanto hacia el ADN celular como a las proteínas de membrana, originando como resultado una foto(geno)toxicidad. En el capítulo 6 se evalúa la fototoxicidad del niraparib (NRP) y su principal metabolito (N-M1). A pesar de que ambos compuestos resultaron ser fototóxicos, dicha fototoxicidad no afectó igual a las principales dianas celulares, ya que el daño fotooxidativo de NRP se observó en lípidos, en proteínas transmembranales y en el ADN celular, mientras que en N-M1 se aprecia fundamentalmente en las proteínas de membrana. Además, la toxicidad observada del NRP en células de cáncer de ovario (A2780 y A2780cis) indicó que este fármaco podría contemplarse como candidato para su uso en un futuro en la terapia fotodinámica para el tratamiento del cáncer de ovario. Finalmente, con todo ello se concluye que estos fármacos de la familia de los inhibidores de la PARP (RCP, TLZ y NRP) son capaces de inducir reacciones de fotosensibilidad, con valores de factor de fotoirritación (PIF) de 41, 7 y 46, respectivamente., [CA] En la present tesi doctoral s'ha desenvolupat una metodologia multidisciplinària per a l'avaluació del potencial fotoquímic i fotobiològic in vitro dels fàrmacs inhibidors de la poli(ADP-ribosa) polimerasa (PARP), combinant tant estudis fotofísics i de caracterització com estudis fotobiològics en biomolècules model i en cultius cel·lulars, concretament en queratinòcits humans immortalitzats (HaCaT). Així, l'objectiu general és investigar si aquests fàrmacs, en combinació amb la radiació solar, són capaços d'induir reaccions de fotosensibilitat i, per tant, poder alertar als oncòlegs d'aquestes fites perquè puguen indicar pautes de fotoprotecció adequades als seus pacients, i així previndre aquests efectes no desitjats. Aquesta tesi es divideix en un total de 7 capítols. En el primer (introducció), es recullen les fites més importants relacionades amb els inhibidors de la PARP, així com un resum sobre les reaccions de fotosensibilització i dels mecanismes químics i biològics involucrats en aquestes. Després d'una exhaustiva cerca bibliogràfica sobre aquests fàrmacs, es va fer un primer estudi dels cinc de la tercera i última generació (rucaparib, talazoparib, niraparib, olaparib i veliparib), identificant així tres d'ells com a possibles agents fotosensibilizants: rucaparib, talazoparib i niraparib, l'estudi del qual es descriu en profunditat en els capítols 4, 5 i 6 de la tesi. En el capítol 4 s'avalua la fototoxicitat del rucaparib (RCP), un fàrmac que, malgrat tindre un cromòfor indole en la seua estructura química, posseeix un desplaçament batocròmic cap a la regió UVA de la llum solar, sent així capaç d'induir reaccions de fotosensibilitat. Mitjançant experiments de fluorescència i fotòlisi de flaix làser es va observar que, després de l¿absorció de llum en aquesta regió de l'espectre, té lloc la generació d'espècies reactives d'oxigen (ROS), que podrien ser les responsables de generar un dany fotooxidatiu cap a l'ADN cel·lular i a les proteïnes transmembranals, originant com a resultat una foto(geno)toxicitat. A més, es va establir que el mecanisme de la mort cel·lular fotoinduïda per RCP és per apoptosi. El capítol 5 se centra en l'avaluació del perfil de fotoseguretat de talazoparib (TLZ), el qual, després de la seua irradiació amb llum UVA dona lloc a un fotoproducte que, després del seu aïllament i caracterització, va resultar no presentar fotorreactivitat ninguna. Aquest fotoproducte va resultar a més ser el responsable de reduir significativament el potencial fototòxic del fàrmac original, ja que no es van detectar espècies transitòries després de la seua irradiació amb llum UVA. A més, per al TLZ es va revelar la producció in vitro de ROS, espècies que podrien ser les responsables de generar un dany fotooxidatiu tant cap a l'ADN cel·lular com a les proteïnes de membrana, originant com a resultat una foto(geno)toxicitat. En el capítol 6 s'avalua la fototoxicitat del niraparib (*NRP) i el seu principal metabòlit (N-M1). A pesar que tots dos compostos van resultar ser fototòxics, aquesta fototoxicitat no va afectar per igual a les principals dianes cel·lulars, ja que el dany fotooxidatiu de NRP es va observar en lípids, en proteïnes i en l'ADN cel·lular, mentre que en N-M1 s'aprecia fonamentalment en les proteïnes de membrana. A més, la toxicitat observada del NRP en cèl·lules de càncer d'ovari (A2780 i A2780cis) va indicar que aquest fàrmac podria contemplar-se com a candidat per al seu ús en un futur en la teràpia fotodinàmica per al tractament del càncer d'ovari. Finalment, amb tot això es conclou que aquests fàrmacs de la família dels inhibidors de la PARP (RCP, TLZ i NRP) són capaços d'induir reaccions de fotosensibilitat, amb valors de factor de fotoirritació (PIF) de 41, 7 i 46, respectivament., [EN] In this doctoral thesis, a multidisciplinary methodology has been performed for the evaluation of the in vitro photochemical and photobiological potential of the poly (ADP-ribose) polymerase (PARP) inhibitors, combining photophysical and photobiological studies in biomolecules and cell cultures, specifically in human immortalized keratinocytes (HaCaT). Thus, the general objective is to investigate if these drugs, in combination with solar radiation, can trigger photosensitivity reactions; this will allow oncologists to indicate appropriate photoprotective guidelines to their patients in order to prevent these undesirable effects. This thesis is divided into 7 chapters. The first one (introduction) contains the essential issues concerning PARP inhibitors, a background of the photosensitization reactions and a description of the involved chemical and biological mechanisms. After in-depth bibliographical research about these drugs, a screening of the five PARP inhibitors (rucaparib, talazoparib, niraparib, olaparib and veliparib) of the third and last generation was carried out, identifying three of them as possible photosensitizing drugs: rucaparib, talazoparib and niraparib. Their behaviour is thoroughly described in chapters 4, 5 and 6. Chapter 4 evaluates the phototoxicity of rucaparib (RCP), a drug that possess an indole chromophore in its chemical structure but displays a bathochromic shift towards the UVA region of sunlight, which makes it able to induce photosensitivity reactions. Generation of reactive oxygen species (ROS) after UVA light absorption was detected by fluorescence and laser flash photolysis experiments. These species could generate photooxidative damage to cellular DNA and transmembrane proteins, resulting in photo(geno)toxicity. In addition, it was established that the mechanism of RCP photoinduced cell death is by apoptosis. Chapter 5 focuses on the photosafety profile of talazoparib (TLZ), a compound that, after UVA irradiation, gives rise to a photooxidized product; after isolation and characterization, the photoproduct did not display any photoreactivity, and no transient species were detected after UVA light irradiation. Therefore, it was responsible for the significantly reduced phototoxic potential of the parent drug. Additionally, for TLZ, in vitro ROS production was detected. These species could lead to photooxidative damage to both cellular DNA and membrane proteins, resulting in photo(geno)toxicity. Chapter 6 deals with the phototoxicity of niraparib (NRP) and its main metabolite (N-M1). Although both compounds are phototoxic, the phototoxicity was found to be different for the main cellular targets: thus, the photooxidative damage of NRP was noticed in lipids, transmembrane proteins and cellular DNA, whereas in N-M1 it was mainly observed in membrane proteins. In addition, NRP was cytotoxic in ovarian cancer cells (A2780 and A2780cis), indicating that this drug could be considered as a future candidate for its use in photodynamic therapy to treat ovarian cancer. Finally, it can be concluded that these PARP inhibitors (RCP, TLZ and NRP) are able to induce photosensitivity disorders, with PIF values of 41, 7 and 46, respectively., We thank the Agencia Estatal de Investigación (PID2020-115010RB-I00/AEI/10.13039/501100011033 and the Generalitat Valenciana (CIAICO/2021/061 and ACIF/2018/153 fellowship for A. M.-P.
RiuNet. Repositorio Institucional de la Universitat Politécnica de Valéncia
Publicación Artículo científico (JournalArticle)

Cellular damage photosensitized by dasatinib, radical-mediated mechanisms and photoprotection in reconstructed epidermis

  • El Ouardi, Meryem
  • Miranda Alonso, Miguel Ángel
  • Tamarit-Mayo, Lorena
  • Vayá Pérez, Ignacio|||0000-0003-1682-9342
  • Andreu, Inmaculada|||0000-0003-3409-9443
[EN] Dasatinib (DAS) is an anticancer drug employed in the treatment of certain hematological malignancies. Although DAS has been mainly developed for oral administration, it has recently garnered attention for its possible topical application. The use of topical drugs can cause photosensitivity, which is not listed as an adverse reaction for DAS. Since DAS absorbs UVA, it could potentially induce photosensitivity reactions and lead to oxidative damage to cellular targets. This study aims to investigate whether DAS exhibits phototoxic reactions on primary cellular targets in both solution and artificial skin, mimicking topical drug administration. It also examines the potential generation of highly reactive intermediates like organic radicals and ROS, which could trigger photosensitivity reactions. Upon DAS irradiation in the UVA region, the first transient species detected was the diradicaloid triplet excited state (3DAS*) with an absorption maximum of around 490 nm, which was quenched by oxygen to produce singlet oxygen. Quenching experiments with linoleic acid and 3-methylindole indicated that radical-mediated (Type I) photosensitized damage to lipids and proteins is possible. However, the lack of triplet quenching with guanosine suggests that the Type II mechanism also plays a role in the photooxidation of biomolecules. Accordingly, the neutral red uptake phototoxicity test (photoirritation factor of 5) and the comet assay, revealed that this drug is photo(geno)toxic to cells. Moreover, investigations on lipid photoperoxidation, and protein and DNA photooxidation strongly support that different cellular compartments are potential targets for DAS-induced phototoxicity. Regarding its potential application in topical dermatological formulations, an O/W emulsion of DAS was prepared and tested in reconstructed human epidermis, and a significant phototoxicity was also demonstrated. Fortunately, this undesired side effect disappeared upon formulation of DAS along with a sunscreen. Thus, for topical treatments, the photosensitivity reactions induced by DAS can be prevented by using formulations including appropriate UVA filters., Financial support from the Spanish Ministry of Science and Innova-tion [PID2020-115010RB-I00/AEI/10.13039/501100011033, and FPU predoctoral fellowship for M. El O.] and from Generalitat Valenciana [CIAICO/2021/061] .
RiuNet. Repositorio Institucional de la Universitat Politécnica de Valéncia
Publicación Artículo científico (JournalArticle)

Switching from ultrafast electron transfer to proton transfer in excited drug-protein complexes upon biotransformation

  • Tamarit-Mayo, Lorena
  • Andreu, Inmaculada|||0000-0003-3409-9443
  • Vayá Pérez, Ignacio|||0000-0003-1682-9342
  • El Ouardi, Meryem
  • Lence, Emilio
  • González-Bello, Concepción
  • Miranda Alonso, Miguel Ángel
[EN] Photosensitization by drugs is directly related with the excited species and the photoinduced processes arising from interaction with UVA light. In this context, the ability of gefitinib (GFT), a tyrosine kinase inhibitor (TKI) used for the treatment of a variety of cancers, to induce phototoxicity and photooxidation of proteins has recently been demonstrated. In principle, photodamage can be generated not only by a given drug but also by its photoactive metabolites that maintain the relevant chromophore. In the present work, a complete study of O-desmorpholinopropyl gefitinib (GFT-MB) has been performed by means of fluorescence and ultrafast transient absorption spectroscopies, in addition to molecular dynamics (MD) simulations. The photobehavior of the GFT-MB metabolite in solution is similar to that of GFT. However, when the drug or its metabolite are in a constrained environment, i.e. within a protein, their behavior and the photoinduced processes that arise from their interaction with UVA light are completely different. For GFT in complex with human serum albumin (HSA), locally excited (LE) singlet states are mainly formed; these species undergo photoinduced electron transfer with Tyr and Trp. By contrast, since GFT-MB is a phenol, excited state proton transfer (ESPT) to form phenolate-like excited species might become an alternative deactivation pathway. As a matter of fact, the protein-bound metabolite exhibits higher fluorescence yields and longer emission wavelengths and lifetimes than GFT@HSA. Ultrafast transient absorption measurements support direct ESPT deprotonation of LE states (rather than ICT), to form phenolate-like species. This is explained by MD simulations, which reveal a close interaction between the phenolic OH group of GFT-MB and Val116 within site 3 (subdomain IB) of HSA. The reported findings are relevant to understand the photosensitizing properties of TKIs and the role of biotransformation in this type of adverse side effects., Financial support from the Spanish Ministry of Science and Innovation (RYC-2015-17737, BEAGAL 18/00211, PID2020-115010RB-I00/AEI/10.13039/501100011033, FPU19/00048, PID2019-105512RB-I00/AEI/10.13039/501100011033), the Xunta de Galicia (ED431C 2021/29), the Centro singular de investigacion de Galicia accreditation 2019-2022 (ED431G 2019/03), and the European Regional Development Fund (ERDF) is gratefully acknowledged. All authors are grateful to the Centro de Supercomputacion de Galicia (CESGA) for use of the Finis Terrae computer.
Minerva. Repositorio Institucional de la Universidad de Santiago de Compostela
Publicación Artículo científico (JournalArticle)

In silico simulations and functional cell studies evidence similar potency and distinct binding of pacific and caribbean ciguatoxins

  • Raposo García, Sandra
  • Castro Alonso, David Miguel
  • Lence Quintana, Emilio José
  • Estévez Bastos, Pablo
  • Leão, José Manuel
  • González Bello, Concepción
  • Gago Martínez, Ana
  • Louzao Ojeda, María del Carmen
  • Botana López, Luis Miguel
Ciguatoxins (CTX) cause ciguatera poisoning, which is the most common reported human food poisoning related to natural marine toxins. Pacific ciguatoxins are the most abundant and studied CTX analogues; however, the growing distribution of Caribbean analogues and the limited data available on their biological effects make necessary to re-evaluate their relative potency. For decades, the guidelines established by regulatory agencies have assumed that the potency of the Caribbean CTXs were tenfold lower than the Pacific CTXs. We present here an integrated study involving Neuro-2a cells (the method used worldwide to test ciguatoxins), electrophysiological assays, and in silico simulations that evidence the similar cytotoxicity of Caribbean and Pacific ciguatoxins and their asymmetry binding within sodium channels. The binding mode of the toxins was first explored by molecular docking using the GOLD program and the resulting binary complexes were further studied by Molecular Dynamics simulation studies using the molecular mechanics force field AMBER. The simulation studies explain their distinct impact on the activation potential of the channel as experimentally observed and provide a detailed picture of the effects caused by these toxins on an atomic scale
Addi. Archivo Digital para la Docencia y la Investigación
Publicación Artículo científico (JournalArticle)

Multi-ancestry genome-wide association study of asthma exacerbations

  • Herrera Luis, Esther
  • Ortega, Victor E.
  • Ampleford, Elizabeth J.
  • Sio, Yang Yie
  • Granell, Raquel
  • de Roos, Emmely
  • Terzikhan, Natalie
  • Elorduy Vergara, Ernesto
  • Hernández Pacheco, Natalia
  • Pérez García, Javier
  • Martín González, Elena
  • Lorenzo Díaz, Fabián
  • Hashimoto, Simone
  • Brinkman, Paul
  • U-BIOPRED Study Group
  • Jorgensen, Andrea L.
  • Yan, Qi
  • Forno, Erick
  • Vijverberg, Susanne J.
  • Lethem, Ryan
  • Espuela Ortiz, Antonio
  • Gorenjak, Mario
  • Eng, Celeste
  • González Pérez, Ruperto
  • Hernández Pérez, José M.
  • Poza Guedes, Paloma
  • Sardón Prado, Olaia
  • Corcuera Elosegui, Paula
  • Hawkins, Greg A.
  • Marsico, Annalisa
  • Bahmer, Thomas
  • Rabe, Klaus F.
  • Hansen, Gesine
  • Kopp, Matthias Volkmar
  • Rios, Raimon
  • Cruz Carmona, María Jesús
  • González Barcala, Francisco Javier
  • Olaguibel, José María
  • Plaza, Vicente
  • Quirce, Santiago
  • Canino, Glorisa
  • Cloutier, Michelle
  • Del Pozo, Victoria
  • Rodríguez Santana, José R.
  • Korta Murua, José Javier
  • Villar, Jesús
  • Potočnik, Uroš
  • Figueiredo, Camila
  • Kabesch, Michael
  • Mukhopadhyay, Somnath
  • Pirmohamed, Munir
  • Hawcutt, Daniel B.
  • Melén, Erik
  • Palmer, Colin N.
  • Turner, Steven
  • Maitland-van der Zee, Anke H.
  • von Mutius, Erika
  • Celedón, Juan C.
  • Brusselle, Guy
  • Chew, Fook Tim
  • Bleecker, Eugene
  • Meyers, Deborah
  • Burchard, Esteban G.
  • Pino Yanes, María
Background: Asthma exacerbations are a serious public health concern due to high healthcare resource utilization, work/school productivity loss, impact on quality of life, and risk of mortality. The genetic basis of asthma exacerbations has been studied in several populations, but no prior study has performed a multi-ancestry meta-analysis of genome-wide association studies (meta-GWAS) for this trait. We aimed to identify common genetic loci associated with asthma exacerbations across diverse populations and to assess their functional role in regulating DNA methylation and gene expression. Methods: A meta-GWAS of asthma exacerbations in 4989 Europeans, 2181 Hispanics/Latinos, 1250 Singaporean Chinese, and 972 African Americans analyzed 9.6 million genetic variants. Suggestively associated variants (p <= 5 x 10(-5)) were assessed for replication in 36,477 European and 1078 non-European asthma patients. Functional effects on DNA methylation were assessed in 595 Hispanic/Latino and African American asthma patients and in publicly available databases. The effect on gene expression was evaluated in silico. Results: One hundred and twenty-six independent variants were suggestively associated with asthma exacerbations in the discovery phase. Two variants independently replicated: rs12091010 located at vascular cell adhesion molecule-1/exostosin like glycosyltransferase-2 (VCAM1/EXTL2) (discovery: odds ratio (ORT allele) = 0.82, p = 9.05 x 10(-6) and replication: ORT allele = 0.89, p = 5.35 x 10(-3)) and rs943126 from pantothenate kinase 1 (PANK1) (discovery: ORC allele = 0.85, p = 3.10 x 10(-5) and replication: ORC allele = 0.89, p = 1.30 x 10(-2)). Both variants regulate gene expression of genes where they locate and DNA methylation levels of nearby genes in whole blood. Conclusions: This multi-ancestry study revealed novel suggestive regulatory loci for asthma exacerbations located in genomic regions participating in inflammation and host defense., This work was funded by the Spanish Ministry of Science and Innovation MCIN/AEI/10.13039/501100011033, and the European Regional Development Fund “ERDF A way of making Europe” by the European Union (SAF2017-83417R), by MCIN/AEI/10.13039/501100011033 (PID2020-116274RB-I00) and by the Allergopharma-EAACI award 2021. This study was also supported by the SysPharmPedia grant from the ERACoSysMed 1st Joint Transnational Call from the European Union under the Horizon 2020. GALA II and SAGE studies were supported by the Sandler Family Foundation, the American Asthma Foundation, the RWJF Amos Medical Faculty Development Program, Harry Wm. and Diana V. Hind Distinguished Professor in Pharmaceutical Sciences II, the National Heart, Lung, and Blood Institute of the National Institutes of Health (R01HL117004, R01HL128439, R01HL135156, X01HL134589, R01HL141992, and R01HL141845), National Institute of Health and Environmental Health Sciences (R01ES015794 and R21ES24844); the National Institute on Minority Health and Health Disparities (NIMHD) (P60MD006902, R01MD010443, and R56MD013312); the National Institute of General Medical Sciences (NIGMS) (RL5GM118984); the Tobacco-Related Disease Research Program (24RT-0025 and 27IR-0030); and the National Human Genome Research Institute (NHGRI) (U01HG009080) to EGB. The PACMAN study was funded by a strategic alliance between GlaxoSmithKline and Utrecht Institute for Pharmaceutical Sciences. The Slovenia study was financially supported by the Slovenian Research Agency (research core funding No. P3-0067) and from SysPharmPediA grant, co-financed by the Ministry of Education, Science and Sport Slovenia (MIZS) (contract number C3330-16-500106). The SHARE Bioresource (GoSHARE) and SHARE have ongoing funding from NHS Research Scotland and were established by funding from The Wellcome Trust Biomedical Resource [Grant No. 099177/Z/12/Z]. Genotyping of samples from BREATHE, PAGES, and GoSHARE was funded by AC15/00015 and conducted at the Genotyping National Centre (CeGEN) CeGen-PRB3-ISCIII; supported by ISCIII and European Regional Development Fund (ERDF) (PT17/0019). ALSPAC was supported by the UK Medical Research Council and Wellcome (102215/2/13/2) and the University of Bristol. The Swedish Heart-Lung Foundation, the Swedish Research Council, and Region Stockholm (ALF project and database maintenance) funded the BAMSE study. The PASS study was funded by the NHS Chair of Pharmacogenetics via the UK Department of Health. U-BIOPRED was funded by the Innovative Medicines Initiative (IMI) Joint Undertaking, under grant agreement no. 115010, resources for which are composed of financial contribution from the European Union's Seventh Framework Programme (FP7/2007-2013) and kind contributions from companies in the European Federation of Pharmaceutical Industries and Associations (EFPIA). Genotyping of samples from GEMAS and MEGA studies was funded by the Spanish Ministry of Science and Innovation (SAF2017-87417R) at the Spanish National Cancer Research Centre, in the Human Genotyping lab, a member of CeGen, PRB3, and was supported by grant PT17/0019, of the PE I+D+i 2013-2016, funded by ISCIII and ERDF. The genotyping of GEMAS was also partially funded by Fundación Canaria Instituto de Investigación Sanitaria de Canarias (PIFIISC19/17). The Rotterdam Study was funded by Erasmus Medical Center and Erasmus University Rotterdam; Netherlands Organization for the Health Research and Development (ZonMw); the Research Institute for Diseases in the Elderly (RIDE); the Ministry of Education, Culture and Science, the Ministry for Health, Welfare and Sports, the European Commission (DG XII), and the Municipality of Rotterdam. ALLIANCE Cohort was funded by grants from the German Federal Ministry of Education and Research (Bundesministerium für Bildung und Forschung, BMBF) as part of the German Centre for Lung Research (DZL) funding. The Hartford-Puerto Rico study was funded by the U.S. National Institutes of Health (grant HL07966 to JCC). MP-Y was funded by the Ramón y Cajal Program (RYC-2015-17205) by MCIN/AEI/10.13039/501100011033 and by the European Social Fund “ESF Investing in your future”. MP-Y and JV were supported by CIBER de Enfermedades Respiratorias, Instituto de Salud Carlos III, Spain (CB/06/06/1088). EH-L was supported by a fellowship awarded by MCIN/AEI/10.13039/501100011033 and by “ESF Investing in your future” (PRE2018-083837). JP-G was supported by a fellowship awarded by Spanish Ministry of Universities (FPU19/02175). AE-O reports funding from the Spanish Ministry of Science, Innovation, and Universities (MICIU) and Universidad de La Laguna (ULL). NH-P was supported by a Medium-Term Research Fellowship by the European Academy of Allergy and Clinical Immunology (EAACI) and a Long-Term Research Fellowship by the European Respiratory Society (ERS) (LTRF202101-00861). UP and MG were supported by the Ministry of Education, Science and Sport of the Republic of Slovenia, grant PERMEABLE (contract number C3330-19-252012). SCSGES results were contributed by authors FTC and YYS. FTC has received research support from the Singapore Ministry of Education Academic Research Fund, Singapore Immunology Network (SIgN), National Medical Research Council (NMRC) (Singapore), Biomedical Research Council (BMRC) (Singapore), and the Agency for Science Technology and Research (A*STAR) (Singapore); Grant Numbers: N-154-000-038-001, R-154-000-191-112, R-154-000-404-112, R-154-000-553-112, R-154-000-565-112, R-154-000-630-112, R-154-000-A08-592, R-154-000-A27-597, R-154-000-A91-592, R-154-000-A95-592, R-154-000-B99-114, BMRC/01/1/21/18/077, BMRC/04/1/21/19/315, SIgN-06-006, SIgN-08-020, NMRC/1150/2008, and H17/01/a0/008. F.T.C. has received consulting fees from Sime Darby Technology Centre; First Resources Ltd; Genting Plantation, and Olam International, outside the submitted work. YYS has received research support from the NUS Resilience & Growth Postdoctoral Fellowships with grant number: R-141-000-036-281. QY conducted the analysis from Hartford-Puerto Rico and United Kingdom Biobank studies. QY was funded by the U.S. National Institutes of Health (HL138098). All funding agencies had no role in the study design, data collection, and analysis, decision to publish, or preparation of the manuscript. The views expressed are those of the authors and not necessarily those of the any funder, National Health Service (NHS), the National Institute for Health Research (NIHR) or the United Kingdom Department of Health.
RODIN. Repositorio de Objetos de Docencia e Investigación de la Universidad de Cádiz
Publicación Artículo científico (JournalArticle)

Cytotoxic sub-nanometer aqueous platinum clusters as potential antitumoral agents

  • Greco, Rossella
  • García-Lainez, Guillermo
  • Oliver-Meseguer, Judit
  • Marini, Carlo
  • Domínguez, Irene
  • López Haro, Miguel
  • Hernández Garrido, Juan Carlos
  • Cerón-Carrasco, José Pedro
  • Andreu, Inmaculada
  • Leyva-Pérez, Antonio
Ligand-free sub-nanometer metal clusters (MCs) of Pt, Ir, Rh, Au and Cu, are prepared here in neat water and used as extremely active (nM) antitumoral agents for HeLa and A2870 cells. The preparation just consists of adding the biocompatible polymer ethylene-vinyl alcohol (EVOH) to an aqueous solution of the corresponding metal salt, to give liters of a MC solution after filtration of the polymer. Since the MC solution is composed of just neat metal atoms and water, the intrinsic antitumoral activity of the different sub-nanometer metal clusters can now fairly be evaluated. Pt clusters show an IC50 of 0.48 mu M for HeLa and A2870 cancer cells, 23 times higher than that of cisplatin and 1000 times higher than that of Pt NPs, and this extremely high cytotoxicity also occurs for cisplatin-resistant (A2870 cis) cells, with a resistance factor of 1.4 (IC50 = 0.68 mu M). Rh and Ir clusters showed an IC50 similar to 1 mu M. Combined experimental and computational studies support an enhanced internalization and cytotoxic activation.
Dipòsit Digital de la UB
Publicación Artículo científico (JournalArticle)

Systems Medicine and Integrated Care to Combat Chronic Noncommunicable Diseases

  • Bousquet, Jean
  • Antó i Boqué, Josep Maria
  • Sterk, Peter J.
  • Adcock, Ian M.
  • Chung, K. Fan, 1951-
  • Roca Elias, Josep
  • Agustí García-Navarro, Àlvar
  • Brightling, Chris
  • Cambon-Thomsen, Anne
  • Cesario, Alfredo
  • Abdelhak, Sonia
  • Antonarakis, Stylianos E.
  • Avignon, Antoine
  • Ballabio, Andrea
  • Bringer, Jacques
  • Dauzat, Michel
  • Ernberg, Ingerman
  • Fabbri, Leonardo M.
  • Froguel, Philippe
  • Galas, David
We propose an innovative, integrated, cost-effective health system to combat major non-communicable diseases (NCDs), including cardiovascular, chronic respiratory, metabolic, rheumatologic and neurologic disorders and cancers, which together are the predominant health problem of the 21st century. This proposed holistic strategy involves comprehensive patient-centered integrated care and multi-scale, multi-modal and multi-level systems approaches to tackle NCDs as a common group of diseases. Rather than studying each disease individually, it will take into account their intertwined gene-environment, socio-economic interactions and co-morbidities that lead to individual-specific complex phenotypes. It will implement a road map for predictive, preventive, personalized and participatory (P4) medicine based on a robust and extensive knowledge management infrastructure that contains individual patient information. It will be supported by strategic partnerships involving all stakeholders, including general practitioners associated with patient-centered care. This systems medicine strategy, which will take a holistic approach to disease, is designed to allow the results to be used globally, taking into account the needs and specificities of local economies and health systems.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Photoprocesses of the tyrosine kinase inhibitor gefitinib: From femtoseconds to microseconds and from solution to cells

  • Tamarit, Lorena
  • El Ouardi, Meryem
  • Andreu, Inmaculada
  • Vayá, Ignacio
  • Miranda, M. A.
Gefitinib (GFT) is a tyrosine kinase inhibitor currently used for the treatment of metastatic non-small cell lung cancer. Although it has been suggested that GFT can be phototoxic, there are no systematic studies on this issue. Here, the photosensitizing potential of GFT has been assessed by means of NRU assays and protein photooxidation. In addition, a thorough photophysical study is presented based on ultrafast transient absorption spectroscopy, fluorescence and laser flash photolysis. Transient species generated after excitation of GFT have been characterized in solution and in biological environments (i.e.HSA and HaCaT cells) to gain insight into the mechanisms involved in photodamage. The photobehavior of GFT was strongly medium-dependent. Excitation of the drug resulted in the formation of locally excited (LE) singlet states (GFT*), which were found to be the main emissive species in non-polar solvents and also within HSA and HaCaT cells. By contrast, in polar solvents, LE states rapidly evolved (∼1 ps) towards the formation of longer-lived intramolecular charge transfer (ICT) states. The triplet excited state of GFT (GFT*) can be formed through intersystem crossing fromGFT* in non-polar solvents and from ICT states in the polar ones, or in the particular case of ethanol, by photosensitization using 2-methoxyacetophenone as an energy donor. In the HSA environment,GFT* was hardly detected due to quenching of its LEGFT* precursor by Trp through an electron transfer process. Accordingly, HSA photooxidation by GFT was demonstrated using the protein carbonylation method. In summary, a good correlation is established between the photophysical behavior and the photobiological properties of GFT, which provides a mechanistic basis for the observed phototoxicity., Financial support from the Spanish Government (RYC-2015-17737, CTQ2017-89416-R, BEAGAL 18/00211, FPU19/00048 and PID2020-115010RB-I00; the Carlos III Institute (ISCIII) of Health, grants: PI16/01877, and CPII16/00052) and Consellería d’Educació, Cultura i Esport (PROMETEO/2017/075) is gratefully acknowledged.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

High-Energy Long-Lived Emitting Mixed Excitons in Homopolymeric Adenine-Thymine DNA Duplexes

  • Vayá, Ignacio
  • Gustavsson, Thomas
  • Markovitsi, Dimitra
The publication deals with polymeric pA•pT and oligomeric A •T DNA duplexes whose fluorescence is studied by time-correlated single photon counting. It is shown that their emission on the nanosecond timescale is largely dominated by high-energy components peaking at a wavelength shorter than 305 nm. Because of their anisotropy (0.02) and their sensitivity to base stacking, modulated by the duplex size and the ionic strength of the solution, these components are attributed to mixed ππ*/charge transfer excitons. As high-energy long-lived excited states may be responsible for photochemical reactions, their identification via theoretical studies is an important challenge., This work was supported by the European Program H2020 MSCA ITN (grant No. 765266—LightDyNAmics project) and the Spanish Agencia Estatal de Investigación (grant number RYC-2015-17737 and project number PID2020-115010RB-I00).
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Cytotoxic sub-nanometer aqueous platinum clusters as potential antitumoral agents

  • Greco, R.
  • García-Laínez, Guillermo
  • Oliver Meseguer, Judit
  • Marini, Carlo
  • Domínguez, I.
  • Lopez-Haro, Miguel
  • Hernández-Garrido, J.C.
  • Cerón-Carrasco, J.P.
  • Andreu, Inmaculada
  • Leyva, Antonio
Ligand-free sub-nanometer metal clusters (MCs) of Pt, Ir, Rh, Au and Cu, are prepared here in neat water and used as extremely active (nM) antitumoral agents for HeLa and A2870 cells. The preparation just consists of adding the biocompatible polymer ethylene-vinyl alcohol (EVOH) to an aqueous solution of the corresponding metal salt, to give liters of a MC solution after filtration of the polymer. Since the MC solution is composed of just neat metal atoms and water, the intrinsic antitumoral activity of the different sub-nanometer metal clusters can now fairly be evaluated. Pt clusters show an IC of 0.48 μM for HeLa and A2870 cancer cells, 23 times higher than that of cisplatin and 1000 times higher than that of Pt NPs, and this extremely high cytotoxicity also occurs for cisplatin-resistant (A2870 cis) cells, with a resistance factor of 1.4 (IC = 0.68 μM). Rh and Ir clusters showed an IC ∼ 1 μM. Combined experimental and computational studies support an enhanced internalization and cytotoxic activation., This work was supported by MINECO (Spain, Projects CTQ 2017-86735-P [AEI/FEDER, UE], PID2020-115010RB-I00, BEAGAL 18/00211, MAT2017-87579-R, IJC2018-036514-I and SEV-2016-0683). Financial support by the project PID2020-115100GB-I00 (funded by Spanish MCIINN, MCIN/AEI/10.13039/501100011033MICIIN) is acknowledged.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Switching from ultrafast electron transfer to proton transfer in excited drug-protein complexes upon biotransformation

  • Tamarit, Lorena
  • El Ouardi, Meryem
  • Lence, Emilio
  • Andreu, Inmaculada
  • González-Bello, Concepción
  • Vayá, Ignacio
  • Miranda, M. A.
Photosensitization by drugs is directly related with the excited species and the photoinduced processes arising from interaction with UVA light. In this context, the ability of gefitinib (GFT), a tyrosine kinase inhibitor (TKI) used for the treatment of a variety of cancers, to induce phototoxicity and photooxidation of proteins has recently been demonstrated. In principle, photodamage can be generated not only by a given drug but also by its photoactive metabolites that maintain the relevant chromophore. In the present work, a complete study of O-desmorpholinopropyl gefitinib (GFT-MB) has been performed by means of fluorescence and ultrafast transient absorption spectroscopies, in addition to molecular dynamics (MD) simulations. The photobehavior of the GFT-MB metabolite in solution is similar to that of GFT. However, when the drug or its metabolite are in a constrained environment, i.e. within a protein, their behavior and the photoinduced processes that arise from their interaction with UVA light are completely different. For GFT in complex with human serum albumin (HSA), locally excited (LE) singlet states are mainly formed; these species undergo photoinduced electron transfer with Tyr and Trp. By contrast, since GFT-MB is a phenol, excited state proton transfer (ESPT) to form phenolate-like excited species might become an alternative deactivation pathway. As a matter of fact, the protein-bound metabolite exhibits higher fluorescence yields and longer emission wavelengths and lifetimes than GFT@HSA. Ultrafast transient absorption measurements support direct ESPT deprotonation of LE states (rather than ICT), to form phenolate-like species. This is explained by MD simulations, which reveal a close interaction between the phenolic OH group of GFT-MB and Val116 within site 3 (subdomain IB) of HSA. The reported findings are relevant to understand the photosensitizing properties of TKIs and the role of biotransformation in this type of adverse side effects., Financial support from the Spanish Ministry of Science and Innovation (RYC-2015-17737, BEAGAL 18/00211, PID2020-115010RB-I00/AEI/10.13039/501100011033, FPU19/00048, PID2019-105512RB-I00/AEI/10.13039/501100011033), the Xunta de Galicia (ED431C 2021/29), the Centro singular de investigación de Galicia accreditation 2019–2022 (ED431G 2019/03), and the European Regional Development Fund (ERDF) is gratefully acknowledged. All authors are grateful to the Centro de Supercomputación de Galicia (CESGA) for use of the Finis Terrae computer.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Singlet oxygen and radical-mediated mechanisms in the oxidative cellular damage photosensitized by the protease inhibitor simeprevir

  • García-Laínez, Guillermo
  • El Ouardi, Meryem
  • Moreno, Alejandro
  • Lence, Emilio
  • González-Bello, Concepción
  • Miranda, M. A.
  • Andreu, Inmaculada
Hepatitis C, a liver inflammation caused by the hepatitis C virus (HCV), is treated with antiviral drugs. In this context, simeprevir (SIM) is an NS3/4A protease inhibitor used in HCV genotypes 1 and 4. It is orally administered and achieves high virological cure rates. Among adverse reactions associated with SIM treatment, photosensitivity reactions have been reported. In the present work, it is clearly shown that SIM is markedly phototoxic, according to the in vitro NRU assay using BALB/c 3T3 mouse fibroblast. This result sheds light on the nature of the photosensitivity reactions induced by SIM in HCV patients, suggesting that porphyrin elevation in patients treated with SIM may not be the only mechanism responsible for SIM-associated photosensitivity. Moreover, lipid photoperoxidation and protein photooxidation assays, using human skin fibroblasts (FSK) and human serum albumin (HSA), respectively, reveal the capability of this drug to promote photodamage to cellular membranes. Also, DNA photo lesions induced by SIM are noticed through comet assay in FSK cells. Photochemical and photobiological studies on the mechanism of SIM-mediated photodamage to biomolecules indicate that the key transient species generated upon SIM irradiation is the triplet excited state. This species is efficiently quenched by oxygen giving rise to singlet oxygen, which is responsible for the oxidation of lipids and DNA (Type II mechanism). In the presence of HSA, the photobehavior is dominated by binding to site 3 of the protein, to give a stable SIM@HSA complex. Inside the complex, quenching of the triplet excited state is less efficient, which results in a longer triplet lifetime and in a decreased singlet oxygen formation. Hence, SIM-mediated photooxidation of the protein is better explained through a radical (Type I) mechanism., Financial support from the Spanish Ministry of Science and Innovation [PID2020-115010RB-I00/AEI/10.13039/501100011033 (I.A), PID2019-105512RB-I00/AEI/10.13039/501100011033 (CG-B) and FPU predoctoral fellowship for M. El O.], Axencia Galega de Innovaci´on (2020-PG067, CG-B), the Xunta de Galicia [ED431C 2021/29 and the Centro singular de investigaci´on de Galicia accreditation 2019–2022 (ED431G 2019/03),], and the European Regional Development Fund (ERDF) is gratefully acknowledged. All authors are grateful to the Centro de Supercomputaci´on de Galicia (CESGA) for use of the Finis Terrae computer., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Solar-driven gas phase photocatalytic CO2 methanation by multimetallic UiO-66 solids decorated with RuOx nanoparticles

  • Cabrero-Antonino, María
  • Melillo, A.
  • Montero-Lanzuela, E.
  • Álvaro Rodríguez, Mercedes
  • Ferrer, B.
  • Vayá, Ignacio
  • Baldoví, Herme G.
  • Navalón, Sergio
As there is an urgent need to produce solar fuels from CO, we here report on the development of a series of multimetallic UiO-66(Zr/Ce/Ti) solids-supported RuO nanoparticles as photocatalysts for selective gas phase CO methanation by H under simulated sunlight irradiation. The trimetallic UiO-66(Zr/Ce/Ti) based-photocatalyst exhibits higher activity (1,900 μmol g of CH after 22 h) than analogous mono- [UiO-66(Zr) or UiO-66(Ce)] and bimetallic [UiO-66(Zr/Ce) or UiO-66(Zr/Ti)] derivatives, as well as higher than previous reports on metal–organic frameworks (MOFs). The experimental evidence on the observed order of photocatalytic activity and insights into the occurrence of a dual photochemical and photothermal mechanism for the most active trimetallic sample were obtained by means of spectroscopic techniques including fluorescence and laser flash photolysis, photoelectrochemical and additional photocatalytic measurements. This study exemplifies the benefits of developing multimetallic MOF-supported metal nanoparticles to achieve high photocatalytic activity for solar-driven gas phase CO conversion., Grant FPU20/03140 funded by MCIN/mAEI/ 10.13039/501100011033 ESF Investing in your future. I.V. thanks the support of grant PID2020-115010RB-I00 funded by MCIN/AEI/10.13039/501100011033. S.N. thanks the support of grant PID2021-123856OB-I00 funded by MCIN/AEI/ 10.13039/501100011033 and by ERDF A way of making Europe. S.N acknowledges the funding for open access charge from “CRUE-Universitat Politècnica de València.”
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Cellular photo(geno)toxicity of gefitinib after biotransformation

  • El Ouardi, Meryem
  • Tamarit, Lorena
  • Vayá, Ignacio
  • Miranda, M. A.
  • Andreu, Inmaculada
Gefitinib (GFT) is a selective epidermal growth factor receptor (EGFR) inhibitor clinically used for the treatment of patients with non-small cell lung cancer. Bioactivation by mainly Phase I hepatic metabolism leads to chemically reactive metabolites such as O-Demethyl gefitinib (DMT-GFT), 4-Defluoro-4-hydroxy gefitinib (DF-GFT), and O-Demorpholinopropyl gefitinib (DMOR-GFT), which display an enhanced UV-light absorption. In this context, the aim of the present study is to investigate the capability of gefitinib metabolites to induce photosensitivity disorders and to elucidate the involved mechanisms. According to the neutral red uptake (NRU) phototoxicity test, only DF-GFT metabolite can be considered non-phototoxic to cells with a photoirritation factor (PIF) close to 1. Moreover, DMOR-GFT is markedly more phototoxic than the parent drug (PIF = 48), whereas DMT-GFT is much less phototoxic (PIF = 7). Using the thiobarbituric acid reactive substances (TBARS) method as an indicator of lipid photoperoxidation, only DMOR-GFT has demonstrated the ability to photosensitize this process, resulting in a significant amount of TBARS (similar to ketoprofen, which was used as the positive control). Protein photooxidation monitored by 2,4-dinitrophenylhydrazine (DNPH) derivatization method is mainly mediated by GFT and, to a lesser extent, by DMOR-GFT; in contrast, protein oxidation associated with DMT-GFT is nearly negligible. Interestingly, the damage to cellular DNA as revealed by the comet assay, indicates that DMT-GFT has the highest photogenotoxic potential; moreover, the DNA damage induced by this metabolite is hardly repaired by the cells after a time recovery of 18 h. This could ultimately result in mutagenic and carcinogenic effects. These results could aid oncologists when prescribing TKIs to cancer patients and, thus, establish the conditions of use and recommend photoprotection guidelines., This research was funded by the MICINN (Grant PID2020-115010RB-I00 funded by MCIN/AEI/10.13039/501100011033, RYC-2015-17737 and FPU predoctoral fellowship for ME.).
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Topological effects in ultrafast photoinduced processes between flurbiprofen and tryptophan in linked dyads and within human serum albumin

  • Tamarit, Lorena
  • García-Gabarda, Laura
  • Jiménez, M. Consuelo
  • Miranda, M. A.
  • Vayá, Ignacio
The interaction dynamics between flurbiprofen (FBP) and tryptophan (Trp) has been studied in covalently linked dyads and within human serum albumin (HSA) by means of fluorescence and ultrafast transient absorption spectroscopy. The dyads have proven to be excellent models to investigate photoinduced processes such as energy and/or electron transfer that may occur in proteins and other biological media. Since the relative spatial arrangement of the interacting units may affect the yield and kinetics of the photoinduced processes, two spacers consisting of amino and carboxylic groups separated by a cyclic or a long linear hydrocarbon chain (1 and 2, respectively) have been used to link the (S)- or (R)-FBP with the (S)-Trp moieties. The main feature observed in the dyads was a strong intramolecular quenching of the fluorescence, which was more important for the (S,S)- than for the (R,S)- diastereomer in dyads 1, whereas the reverse was true for dyads 2. This was consistent with the results obtained by simple molecular modelling (PM3). The observed stereodifferentiation in (S,S)-1 and (R,S)-1 arises from the deactivation of Trp*, while in (S,S)-2 and (R,S)-2 it is associated with FBP*. The mechanistic nature of FBP* quenching is ascribed to energy transfer, while for Trp* it is attributed to electron transfer and/or exciplex formation. These results are consistent with those obtained by ultrafast transient absorption spectroscopy, where FBP* was detected as a band with a maximum at ca. 425 nm and a shoulder at ∼375 nm, whereas Trp did not give rise to any noticeable transient. Interestingly, similar photoprocesses were observed in the dyads and in the supramolecular FBP@HSA complexes. Overall, these results may aid to gain a deeper understanding of the photoinduced processes occurring in protein-bound drugs, which may shed light on the mechanistic pathways involved in photobiological damage., Grant PID2020-115010RB-I00 funded by MCIN/AEI/10.13039/501100011033 and grant from Conselleria d’Innovació, Universitats, Ciència i Societat Digital (CIAICO/2021/061) are gratefully acknowledged.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Solar-assisted photocatalytic water splitting using defective UiO-66solids from modulated synthesis

  • Rueda-Navarro, Celia M.
  • Cabrero-Antonino, María
  • Escamilla, Paula
  • Díez-Cabanes, Valentín
  • Fan, Dong
  • Atienzar, Pedro
  • Ferrer, B.
  • Vayá, Ignacio
  • Maurin, Guillaume
  • Baldoví, Herme G.
  • Navalón, Sergio
C. M. R. thanks the support of PRE2019-089877 funded by MCIN/AEI/10.13039/501100011033 and by ESF Investing in your future. V. D-C. is grateful to the European Union’s Horizon 2020 Research and Innovation Program project MOF2H2 (GA No. 101084131) for the financial support. Computational ressources were provided by the Centre informatique national de l’enseignement supérieur (CINES) Supercomputing facilities and the local ICGM clusters. I. V. thanks the support of grant PID2020-115010RB-I00 funded by MCIN/AEI/10.13039/501100011033. S. N. thanks the support of grant PID2021-123856OBI00 funded by MCIN/AEI/10.13039/501100011033 and by ERDF A way of making Europe., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Solar Gas-Phase CO2 Hydrogenation by Multifunctional UiO-66 Photocatalysts

  • Rueda-Navarro, Celia M.
  • Abou Khalil, Zahraa
  • Melillo, A.
  • Ferrer, B.
  • Montero, R.
  • Longarte Aldama, Asier
  • Daturi, Marco
  • Vayá, Ignacio
  • El-Roz, M.
  • Martínez-Martínez, Virginia
  • Baldoví, Herme G.
  • Navalón, Sergio
Solar-assisted CO conversion into fuels and chemical products involves a range of technologies aimed at driving industrial decarbonization methods. In this work, we report on the development of a series of multifunctional metal-organic frameworks (MOFs) based on nitro- or amino-functionalized UiO-66(M) (M: Zr or Zr/Ti) supported RuO NPs as photocatalysts, having different energy band level diagrams, for CO hydrogenation under simulated concentrated sunlight irradiation. RuO(1 wt %; 2.2 ± 0.9 nm)@UiO-66(Zr/Ti)-NO was found to be a reusable photocatalyst, to be selective for CO methanation (5.03 mmol g after 22 h;, apparent quantum yield at 350, 400, and 600 nm of 1.67, 0.25, and 0.01%, respectively), and to show about 3-6 times activity compared with previous investigations. The photocatalysts were characterized by advanced spectroscopic techniques like femto- and nanosecond transient absorption, spin electron resonance, and photoluminescence spectroscopies together with (photo)electrochemical measurements. The photocatalytic CO methanation mechanism was assessed by operando FTIR spectroscopy. The results indicate that the most active photocatalyst operates under a dual photochemical and photothermal mechanism. This investigation shows the potential of multifunctional MOFs as photocatalysts for solar-driven CO recycling., C.M.R.N. thanks the support of PRE2019-089877 funded by MICIU/AEI/10.13039/501100011033. I.V. thanks the support of grant PID2020-115010RB-I00 funded by MICIU/AEI/10.13039/501100011033. A.L. thanks the support from the MICIU through grant PID2021-127918NB-I00. V.M.M. thanks financial support of grants PID2020-114347RB-C32 funded by MICIU/AEI/10.13039/501100011033 as well as Vasco-Eusko Jaurlaritza (project IT1639-22) and by ERDF “A way of making Europe”. The METHASOL project receives funding from the European Union Horizon 2020 research and innovation programme under Grant Agreement N°10102264. Funding for open access charge: CRUE-Universitat Politècnica de València. S.N. thanks the support of grant PID2021-123856OBI00 funded by MICIU/AEI/10.13039/501100011033 and by ERDF “A way of making Europe”.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Modulation of the photobehavior of gefitinib and its phenolic metabolites by human transport proteins

  • Tamarit, Lorena
  • El Ouardi, Meryem
  • Lence, Emilio
  • Andreu, Inmaculada
  • González-Bello, Concepción
  • Miranda, M. A.
  • Vayá, Ignacio
The photobiological damage that certain drugs or their metabolites can photosensitize in proteins is generally associated with the nature of the excited species that are generated upon interaction with UVA light. In this regard, the photoinduced damage of the anticancer drug gefitinib (GFT) and its two main photoactive metabolites GFT-M1 and GFT-M2 in cellular milieu was recently investigated. With this background, the photophysical properties of both the drug and its metabolites have now been studied in the presence of the two main transport proteins of human plasma, i.e., serum albumin (HSA) and α1-acid glycoprotein (HAG) upon UVA light excitation. In general, the observed photobehavior was strongly affected by the confined environment provided by the protein. Thus, GFT-M1 (which exhibits the highest phototoxicity) showed the highest fluorescence yield arising from long-lived HSA-bound phenolate-like excited species. Conversely, locally excited (LE) states were formed within HAG, resulting in lower fluorescence yields. The reserve was true for GFT-M2, which despite being also a phenol, led mainly to formation of LE states within HSA, and phenolate-like species (with a minor contribution of LE) inside HAG. Finally, the parent drug GFT, which is known to form LE states within HSA, exhibited a parallel behavior in the two proteins. In addition, determination of the association constants by both absorption and emission spectroscopy revealed that the two metabolites bind stronger to HSA than the parent drug, whereas smaller differences were observed for HAG. This was further confirmed by studying the competing interactions between GFT or its metabolites with the two proteins using fluorescence measurements. These above experimental findings were satisfactorily correlated with the results obtained by means of molecular dynamics (MD) simulations, which revealed the high affinity binding sites, the strength of interactions and the involved amino acid residues. In general, the differences observed in the photobehavior of the drug and its two photoactive metabolites in protein media are consistent with their relative photosensitizing potentials., The author(s) declare that financial support was received for the research, authorship, and/or publication of this article. Grants PID2020-115010RB-I00 and PID2022-136963OB-I00 funded by MCIN/AEI/10.13039/501100011033, grant CIAICO/2021/061 funded by Conselleria d’Innovació, Universitats, Ciència i Societat Digital and grant AP2022-5 funded by Programa d'Accions Preparatòries UV-La Fe. Grants from the Xunta de Galicia [ED431C 2021/29 and the Centro singular de investigación de Galicia accreditation 2019-2022 (ED431G 2019/03), CG-B], and the European Regional Development Fund (ERDF).
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Photolytic splitting of homodimeric quinone-derived oxetanes studied by ultrafast transient absorption spectroscopy and quantum chemistry

  • Blasco-Brusola, A.
  • Tamarit, Lorena
  • Navarrete-Miguel, M.
  • Roca-Sanjuán, Daniel
  • Miranda, M. A.
  • Vayá, Ignacio
The photoinduced cycloreversion of oxetane derivatives is of considerable biological interest since these compounds are involved in the photochemical formation and repair of the highly mutagenic pyrimidine (6-4) pyrimidone DNA photoproducts ((6-4)PPs). Previous reports have dealt with the photoreactivity of heterodimeric oxetanes composed mainly of benzophenone (BP) and thymine (Thy) or uracil (Ura) derivatives. However, these models are far from the non-isolable Thy〈º〉Thy dimers, which are the real precursors of (6-4)PPs. Thus, we have synthesized two chemically stable homodimeric oxetanes through the Paternò-Büchi reaction between two identical enone units, i.e. 1,4-benzoquinone (BQ) and 1,4-naphthoquinone (NQ), that led to formation of BQ-Ox and NQ-Ox, respectively. Their photoreactivity has been studied by means of steady-state photolysis and transient absorption spectroscopy from the femtosecond to the microsecond time scale. Thus, photolysis of BQ-Ox and NQ-Ox led to formation of the monomeric BQ or NQ, respectively, through ring opening in a “non-adiabatic” process. Accordingly, the transient absorption spectra of the triplet excited quinones (BQ* and NQ*) were not observed as a result of direct photolysis of the quinone-derived oxetanes. In the case of NQ-Ox, a minor signal corresponding to NQ* was detected; its formation was ascribed to minor photodegradation of the oxetane during acquisitions of the spectra during the laser experiments. These results are supported by computational analyses based on density functional theory and multiconfigurational quantum chemistry (CASSCF/CASPT2); here, an accessible conical intersection between the ground and excited singlet states has been characterized as the main structure leading to deactivation of excited BQ-Ox or NQ-Ox. This behavior contrasts with those previously observed for heterodimeric thymine-derived oxetanes, where a certain degree of ring opening into the excited triplet state is observed., Grants PID2020-115010RB-I00 and PID2021-127199NB-I00 funded by MCIN/AEI/10.13039/501100011033 and grants from Conselleria d’Innovació, Universitats, Ciència i Societat Digital (CIAICO/2021/061, CIAICO/2022/121 and CIAPOS/2021/87) are gratefully acknowledged. M. N.-M. is thankful to the Universitat de València for her “Atracció de Talent 2020” predoctoral grant. The authors would like to thank the use of RIAIDT-USC analytical facilities for the X-ray crystallography analysis.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Cellular damage photosensitized by dasatinib, radical-mediated mechanisms and photoprotection in reconstructed epidermis

  • El Ouardi, Meryem
  • Tamarit, Lorena
  • Vayá, Ignacio
  • Miranda, M. A.
  • Andreu, Inmaculada
Dasatinib (DAS) is an anticancer drug employed in the treatment of certain hematological malignancies. Although DAS has been mainly developed for oral administration, it has recently garnered attention for its possible topical application. The use of topical drugs can cause photosensitivity, which is not listed as an adverse reaction for DAS. Since DAS absorbs UVA, it could potentially induce photosensitivity reactions and lead to oxidative damage to cellular targets. This study aims to investigate whether DAS exhibits phototoxic reactions on primary cellular targets in both solution and artificial skin, mimicking topical drug administration. It also examines the potential generation of highly reactive intermediates like organic radicals and ROS, which could trigger photosensitivity reactions. Upon DAS irradiation in the UVA region, the first transient species detected was the diradicaloid triplet excited state (DAS∗) with an absorption maximum of around 490 nm, which was quenched by oxygen to produce singlet oxygen. Quenching experiments with linoleic acid and 3-methylindole indicated that radical-mediated (Type I) photosensitized damage to lipids and proteins is possible. However, the lack of triplet quenching with guanosine suggests that the Type II mechanism also plays a role in the photooxidation of biomolecules. Accordingly, the neutral red uptake phototoxicity test (photoirritation factor of 5) and the comet assay, revealed that this drug is photo(geno)toxic to cells. Moreover, investigations on lipid photoperoxidation, and protein and DNA photooxidation strongly support that different cellular compartments are potential targets for DAS-induced phototoxicity. Regarding its potential application in topical dermatological formulations, an O/W emulsion of DAS was prepared and tested in reconstructed human epidermis, and a significant phototoxicity was also demonstrated. Fortunately, this undesired side effect disappeared upon formulation of DAS along with a sunscreen. Thus, for topical treatments, the photosensitivity reactions induced by DAS can be prevented by using formulations including appropriate UVA filters., Financial support from the Spanish Ministry of Science and Innovation [PID2020-115010RB-I00/AEI/10.13039/501100011033, and FPU predoctoral fellowship for M. El O.] and from Generalitat Valenciana [CIAICO/2021/061].
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Towards a European health research and innovation cloud (HRIC)

  • Aarestrup, Frank M.
  • Gut, Ivo Glynne
  • Sanz, Ferran
  • Van Oyen, Herman
The European Union (EU) initiative on the Digital Transformation of Health and Care (Digicare) aims to provide the conditions necessary for building a secure, flexible, and decentralized digital health infrastructure. Creating a European Health Research and Innovation Cloud (HRIC) within this environment should enable data sharing and analysis for health research across the EU, in compliance with data protection legislation while preserving the full trust of the participants. Such a HRIC should learn from and build on existing data infrastructures, integrate best practices, and focus on the concrete needs of the community in terms of technologies, governance, management, regulation, and ethics requirements. Here, we describe the vision and expected benefits of digital data sharing in health research activities and present a roadmap that fosters the opportunities while answering the challenges of implementing a HRIC. For this, we put forward five specific recommendations and action points to ensure that a European HRIC: i) is built on established standards and guidelines, providing cloud technologies through an open and decentralized infrastructure; ii) is developed and certified to the highest standards of interoperability and data security that can be trusted by all stakeholders; iii) is supported by a robust ethical and legal framework that is compliant with the EU General Data Protection Regulation (GDPR); iv) establishes a proper environment for the training of new generations of data and medical scientists; and v) stimulates research and innovation in transnational collaborations through public and private initiatives and partnerships funded by the EU through Horizon 2020 and Horizon Europe., The workshop participants received funding from the European Union Seventh Program for Research, Technological Development and Demonstration (FP7) and Horizon Research and Innovation Program (H2020) and other European Union programs under the following grant agreements: AETIONOMY (Developing an Aetiology-based Taxonomy of Human Disease—Approaches to Develop a New Taxonomy for Neurological Disorders, IMI-no115568), ANTI-SUPERBUG PCP (ANTISUPERBUG Precommercial Procurement, H2020-no688878), B-CAST (Breast CAncer Stratification understanding the determinants of risk and prognosis of molecular sub-types, H2020-no633784), BRIDGE Health (Bridging information and data generation for evidence-based health policy and research, H2020-no664691), CASyM (Coordinating Action Systems Medicine—Implementation of Systems Medicine across Europe, FP7-n°305033), CENTER-TBI (Collaborative European NeuroTrauma Effectiveness Research in TBI, FP7-no602150), CECM (Centre for New Methods in Computational Diagnostics and Personalized Therapy, H2020-no763734), COLOSSUS (Advancing a Precision Medicine Paradigm in Metastatic Colorectal Cancer: Systems based patient stratification solutions, H2020-no754923), COMPARE (COllaborative Management Platform for detection and Analyses of (Re-)emerging and foodborne outbreaks in Europe, H2020-no643476), CONNECARE (Personalized Connected Care for Complex Chronic Patients, H2020-no689802), CREATIVE (Collaborative REsearch on ACute Traumatic brain Injury in intensiVe care medicine in Europe, FP7-no602714), DEFORM (Define the global and financial impact of research misconduct H2020-no710246), ECCTR (European Cornea and Cell Transplant Registry, FP7-n°709723), E-COMPARED (European COMPARative Effectiveness Research on online Depression, FP7-no603098), ECRIN-IA (European Clinical Research Infrastructures Network- Integrating Activity, FP7-no284395), EHR4CR (Electronic Health Records Systems for Clinical Research, IMI-no115189) eInfraCentral (European E-infrastructures Services Gateway, H2020-no731049), ELIXIR (European Life-science Infrastructure for Biological Information, FP7-n°211601), ELIXIR-EXCELERATE (Fast track ELIXIR implementation and drive early user exploitation across the life sciences, H2020-no676559), eMEN (e-mental health innovation and transnational implementation platform North West Europe, H2020), EMIF (European Medical Information Framework, IMI-no115372), ERA PerMed (ERA-net Cofund in Personalized Medicine, H2020-no779282), eTRIKS (Delivering European Translational Information and Knowledge Management Services, IMI-1-no115446), EuroPOND (Data-driven models for progression of neurological diseases, H2020-n°666992), EurValve (Personalized Decision Support for Heart Valve disease, H2020-no689617), HBP SGA1/SGA2 (Human Brain Project specific grant agreements, H2020-n°720270/785907), ICT4DEPRESSION (User-friendly ICT tools to enhance self-management and effective treatment of depression in the EU, FP7-n°248778), ImpleMentAll (Towards evidence-based tailored implementation strategies for eHealth, H2020-no733025), INSTRUCT-ULTRA (Releasing the full potential of instruct to expand and consolidate infrastructure services for integrated structural life sciences research, H2020-no731005), MASTERMIND (Management of Mental Disorders through Advanced Technologies, CIP-no621000), MeDALL (Mechanisms of the Development of ALLergy, FP7-n°261357), MedBioinformatics (Creating medically-driven integrative bioinformatics applications focused on oncology, CNS disorders and their comorbidities, H2020-n°634143), MIDAS (Meaningful Integration of Data, Analytics and Services, H2020-no727721), MultipleMS (Multiple manifestations of genetic and non-genetic factors in Multiple Sclerosis disentangled with a multi-omics approach to accelerate personalized medicine, H2020-no733161), myPEBS (Randomized Comparison Of Risk-Stratified versus Standard Breast Cancer Screening European Women Aged 40–74, H2020-no755394), OpenAIRE-Advance (Advancing Open Scholarship, H2020-no777541), OpenMedicine (OpenMedicine, H2020-n°643796), PanCareSurFup (PanCare Childhood and Adolescent Cancer Survival Care and Follow-up Studies, FP7-n°257505), PIONEER (Prostate Cancer DIagnOsis and TreatmeNt Enhancement through the Power of Big Data in EuRope, H2020-IMI-2-n°777492), PREPARE (Platform for European Preparedness Against (Re-)emerging Epidemics, FP7-n°602525), Regions4PerMed (Interregional coordination for a deep and fast uptake of personalized health, H2020-no825812), RD-CONNECT (An integrated platform connecting registries, biobanks and clinical bioinformatics for rare disease research, FP7-no305344), Solve-RD (Solving the unsolved Rare Diseases, H2020-no779257), SPIDIA4P (SPIDIA for Personalized Medicine-Standardization of generic Pre-analytical procedures for In-vitro DIAgnostics for Personalized Medicine, H2020-no733112), SYSCID (A Systems medicine approach to chronic inflammatory disease, H2020-no733100), SysCLAD (Systems prediction of Chronic Allograft Dysfunction, FP7-n°305457), SYSCOL (Systems Biology of Colorectal Cancer, FP7-no258236), SysMedPD (Systems Medicine of Mitochondrial Parkinson’s Disease, H2020-n°668738), U-BIOPRED (Unbiased BIOmarkers for the PREDiction of respiratory disease outcomes, IMI-n°115010), VPH-share (Virtual Physiological Human: Sharing for Healthcare—A Research Environment, FP7-n°269978).
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Blood eosinophil count and airway epithelial transcriptome relationships in COPD versus asthma

  • George, Leena
  • Esteve-Codina, Anna
  • Soler Artigas, María
  • Thun, Gian Andri
  • Heath, Simon
  • Gut, Ivo Glynne
  • Brightling, Christopher E.
BACKGROUND: Whether the clinical or pathophysiologic significance of the "treatable trait" high blood eosinophil count in COPD is the same as for asthma remains controversial. We sought to determine the relationship between the blood eosinophil count, clinical characteristics and gene expression from bronchial brushings in COPD and asthma. METHODS: Subjects were recruited into a COPD (emphysema versus airway disease [EvA]) or asthma cohort (Unbiased BIOmarkers in PREDiction of respiratory disease outcomes, U-BIOPRED). We determined gene expression using RNAseq in EvA (n = 283) and Affymetrix microarrays in U-BIOPRED (n = 85). We ran linear regression analysis of the bronchial brushings transcriptional signal versus blood eosinophil counts as well as differential expression using a blood eosinophil > 200 cells/μL as a cut-off. The false discovery rate was controlled at 1% (with continuous values) and 5% (with dichotomized values). RESULTS: There were no differences in age, gender, lung function, exercise capacity and quantitative computed tomography between eosinophilic versus noneosinophilic COPD cases. Total serum IgE was increased in eosinophilic asthma and COPD. In EvA, there were 12 genes with a statistically significant positive association with the linear blood eosinophil count, whereas in U-BIOPRED, 1197 genes showed significant associations (266 positive and 931 negative). The transcriptome showed little overlap between genes and pathways associated with blood eosinophil counts in asthma versus COPD. Only CST1 was common to eosinophilic asthma and COPD and was replicated in independent cohorts. CONCLUSION: Despite shared "treatable traits" between asthma and COPD, the molecular mechanisms underlying these clinical entities are predominately different., This work was funded in part by Airway Disease Predicting Outcomes through Patient Specific Computational Modelling (AirPROM) project (funded through FP7 EU grant), U‐BIOPRED (IMI) (No. 115010), eTRIKS (IMI) (No. 115446), Emphysema versus Airways Disease (EvA FP7; 200506)
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Systems Medicine and Integrated Care to Combat Chronic Noncommunicable Diseases

  • Bousquet, Jean
  • Antó i Boqué, Josep Maria
  • Sterk, Peter J.
  • Adcock, Ian M.
  • Chung, K. Fan, 1951-
  • Roca Elias, Josep
  • Agustí García-Navarro, Àlvar
  • Brightling, Chris
  • Cambon-Thomsen, Anne
  • Cesario, Alfredo
  • Abdelhak, Sonia
  • Antonarakis, Stylianos E.
  • Avignon, Antoine
  • Ballabio, Andrea
  • Bringer, Jacques
  • Dauzat, Michel
  • Ernberg, Ingerman
  • Fabbri, Leonardo M.
  • Froguel, Philippe
  • Galas, David
We propose an innovative, integrated, cost-effective health system to combat major non-communicable diseases (NCDs), including cardiovascular, chronic respiratory, metabolic, rheumatologic and neurologic disorders and cancers, which together are the predominant health problem of the 21st century. This proposed holistic strategy involves comprehensive patient-centered integrated care and multi-scale, multi-modal and multi-level systems approaches to tackle NCDs as a common group of diseases. Rather than studying each disease individually, it will take into account their intertwined gene-environment, socio-economic interactions and co-morbidities that lead to individual-specific complex phenotypes. It will implement a road map for predictive, preventive, personalized and participatory (P4) medicine based on a robust and extensive knowledge management infrastructure that contains individual patient information. It will be supported by strategic partnerships involving all stakeholders, including general practitioners associated with patient-centered care. This systems medicine strategy, which will take a holistic approach to disease, is designed to allow the results to be used globally, taking into account the needs and specificities of local economies and health systems.
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Systems medicine and integrated care to combat chronic noncommunicable diseases

  • Bousquet, Jean
  • Antó i Boqué, Josep Maria
  • Auffray, Charles
We propose an innovative, integrated, cost-effective health system to combat major non-communicable diseases (NCDs), including cardiovascular, chronic respiratory, metabolic, rheumatologic and neurologic disorders and cancers, which together are the predominant health problem of the 21st century. This proposed holistic strategy involves comprehensive patient-centered integrated care and multi-scale, multi-modal and multi-level systems approaches to tackle NCDs as a common group of diseases. Rather than studying each disease individually, it will take into account their intertwined gene-environment, socio-economic interactions and co-morbidities that lead to individual-specific complex phenotypes. It will implement a road map for predictive, preventive, personalized and participatory (P4) medicine based on a robust and extensive knowledge management infrastructure that contains individual patient information. It will be supported by strategic partnerships involving all stakeholders, including general practitioners associated with patient-centered care. This systems medicine strategy, which will take a holistic approach to disease, is designed to allow the results to be used globally, taking into account the needs and specificities of local economies and health systems., Part of the conceptual work presented has received support from the European commission FP7 projects AIRProm (Grant Agreement FP7 270194), BioSHaRE-EU (Grant Agreement FP7 261433), MeDALL (Grant Agreement FP7 264357), SYNERGY-COPD (Grant Agreement) and U-BIOPRED (Grant Agreement IMI 115010). JB, JMA, AC-T, FK, MLK, SP, CP and CA were supported by MeDALL; PJS, IMA and KFC were supported by U-BIOPRED; JR and AA were supported by SYNERGY-COPD; CB was supported by AIRProm; AC-T was supported by BioSHaRE-EU